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Mucosal surfaces 
Mucosal surfaces are the largest and most important interface between the 
human body and its environment and they comprise a total area of 
approximately 300 m2 of intimate contacts between the organism and the 
environment. Interaction with the environment is of vital importance for the 
uptake of nutrients and oxygen and excretion of waste products, but also makes 
the body vulnerable for infection and damage (Tlaskalova-Hogenova et al., 
2005). The external environment may have large quantities of antigenic, 
mitogenic and toxic stimuli in food and in the air together with pathogenic 
bacteria and viruses as well. To overcome these continuing challenges the 
immune system has developed extensive innate and adaptive responses.  
The oral cavity is a part of the mucosal immune system. It is covered by 
saliva, which harbours a similar set of protective proteins as other mucosal fluids 
(Schenkels et al., 1995). A major role of saliva is to control the oral microbial 
ecosystem. This becomes manifest when the secretion of saliva is disturbed, e.g. 
after radiation therapy for treatment of head and neck cancer, by auto-immune 
diseases affecting glandular tissues, such as Sjögren’s syndrome, or as a side 
effect of numerous drugs. Under these conditions both qualitative and 
quantitative changes in the oral microflora occur. Altogether, saliva is important 
for maintenance of the oral health. In the absence of saliva it becomes extremely 
difficult to maintain the oral tissues healthy, both the mucosa and the dental 
enamel (Nieuw Amerongen and Veerman, 2002).  
  
Saliva secretion 
Whole saliva is for the greater part composed of secretions from three pairs of 
major salivary glands (parotid, submandibular, and sublingual) and from 
numerous minor ones (labial, buccal, lingual, palatal) (Figure 1). Each type of 
salivary gland secretes a fluid with a characteristic protein composition, 
designated glandular saliva (Veerman et al., 1996). At night and in rest, mainly 
the (sero)mucous submandibular and sublingual glands are active. Together 
with the numerous minor salivary glands, they are the main contributors of the 
salivary mucins, mucous glycoproteins, consisting of two types: the large 
MUC5B, and the smaller MUC7 (Nieuw Amerongen et al., 1995). The large 
salivary mucins (MUC5B) are responsible for the characteristic visco-elastic and 
slimy properties of mucous saliva (Veerman et al., 1989; Van der Reijden et al., 
1993). The smaller MUC7 is particularly involved in the interaction with 
micro-organisms. During daytime, also the parotid glands contribute to whole 
saliva, varying from 25% in resting whole saliva up to 60% in whole saliva 
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stimulated by mastication. In contrast to secretions from the other major 
salivary glands, parotid saliva, lacking mucins, is a thin water-like (serous) saliva.  
 
 
 
Figure 1. Location of the three major salivary glands. PAR, parotid gland; SL, sublingual 
gland; SM, submandibular gland. Besides these major glands there are numerous minor glands 
spread throughout the oral cavity, such as the palatum, cheek, lower lip. (Adapted from Netter 
F. H. 1959. The ciba collection of medical illustrations Vol. 3, pt 1) 
 
Protective role of saliva 
Saliva is essential for a lifelong conservation of the dentition. Without saliva the 
oral mucosa becomes highly vulnerable to infection and inflammation and the 
teeth undergo easily mechanical wear (Nieuw Amerongen et al., 1987). Various 
functions of saliva are implicated in the maintenance of oral health and the 
protection of our dentition (Figure 2).  
All oral surfaces are covered by a slimy layer consisting mainly of mucins. These 
large glycoproteins act as a diffusion barrier impeding the entry of noxious 
agents, including protons, micro-organisms and viruses. The mucous layer helps 
in reducing the friction between antagonistic tooth surfaces, and in this way 
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diminishes dental wear. A film of salivary proteins, called the acquired enamel 
pellicle, protects the tooth surface against wear. The most important pellicle 
proteins are, in addition to mucins, the proline-rich proteins and statherin. 
Proline-rich proteins (PRP) and statherin promote remineralization of calcium 
hydroxyapatite, the mineral phase of dental enamel, by binding calcium ions 
(Schlesinger et al., 1987; Schlesinger et al., 1989; Lamkin et al., 1996), both on 
the dental surface and in solution.  
 
Figure 2. The various functions of saliva.  (Adapted from Levine, 1993)  
 
The role of saliva in the context of oral colonization of micro-organisms is 
ambiguous, since it both inhibits and supports specifically microbial 
colonization. Some salivary proteins directly kill micro-organisms, for instance 
lysozyme, histatins, defensins and the cathelicidin LL-37, or inhibit their 
growth, like cystatins and lactoferrin (Helmerhorst et al., 1997; Edgerton et al., 
2000; Abiko et al., 2002; Murakami et al., 2002; Woo et al., 2003). On the 
other hand, salivary proteins can serve as a nutrient source for micro-organisms. 
Especially the carbohydrate side chains of MUC5B, comprising up to 90 % of 
its molecular mass, are used as a nutrient source. Due to the heterogeneity of 
these carbohydrate side chains a large set of enzymes is required for complete 
degradation. Since each micro-organism only produces a limited set of enzymes 
a consortium of micro-organisms is necessary to use the full potential of mucins 
as a nutrient. In this way, the heterogeneity of the oral microflora may be 
modulated by saliva (van der Hoeven et al., 1990; van der Hoeven and Camp, 
1991).  
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 Salivary components also enhance colonization of micro-organisms by 
forming receptors for bacterial adhesion on oral surfaces. In solution the very 
same salivary components may bind to micro-organisms thereby competitively 
inhibiting colonization and invasion into oral tissues. Salivary components that 
bind to micro-organisms, thereby agglutinating them, are MUC7, salivary 
agglutinin (SAG), s-IgA and proline-rich glycoprotein (Nieuw Amerongen and 
Veerman, 2002; Nieuw Amerongen et al., 2004).  
 In this thesis special attention is given to salivary interaction with the 
opportunistic fungus Candida albicans. 
  
Candida albicans 
Besides bacteria, yeasts commonly inhabit the oral cavity, in particular C. 
albicans. The presence of C. albicans in the oral cavity of healthy individuals 
varies from 35 to 60% of the population, yet candidiasis occurs much less 
frequently and is related to several, often host-related, factors. For instance, 
individuals with a compromised immune system, e.g. HIV patients or patients 
under immunosuppressive medication, frequently suffer from Candida 
infections in various parts of the body, including the skin, oral cavity and 
esophagus, gastrointestinal tract and vagina. In the oral cavity Candida infection 
is sometimes visible as thrush, white/yellowish creamlike patches on the oral 
mucosa and the tongue.  
 An important property that contributes to the virulence of C. albicans is its 
ability to switch from the planktonic (yeast) to the filamentous (hyphal) growth 
form (Sanchez-Martinez and Perez-Martin, 2001; Whiteway and Bachewich, 
2007; Cottier and Muhlschlegel, 2009; Soll, 2009). Each growth form has 
different properties which makes it possible for C. albicans to adjust to a variety 
of environmental conditions (Whiteway and Bachewich, 2007; Cottier and 
Muhlschlegel, 2009). The hyphal form is adhesive, can penetrate human 
mucosal and epithelial tissues and is therefore considered to be the most 
invasive form. The yeast form is much less adhesive and incapable of protruding 
through host tissue. On the other hand, it can easily be transported via the 
blood circulatory system promoting dissemination of the infection through the 
whole body (Grubb et al., 2009).  
Many authors make a difference between hyphae and pseudo-hyphae. Just like 
hyphae, pseudo-hyphae are elongated, but in pseudo-hyphae each cell-cell 
junction is constricted and the diameter of the cells is in the middle wider than 
at the ends. In contrast, hyphae cells are parallel without constrictions at cell 
junctions. There has been discussion about whether pseudo-hyphae are an 
Chapter 1   
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intermediate form between hyphae and yeasts or a physiologically distinct form. 
Carlisle et al. (Carlisle et al., 2009) showed that formation of both hyphae and 
pseudo-hyphae is triggered by activation of the UME6 gene, a zinc finger 
transcription factor that regulates hyphae formation.  
  Several salivary proteins and peptides have been reported to interact 
with C. albicans, among which LL-37, histatins, defensins, IgA, lactoferrin, 
PRPs and MUC7 (Sigurdardottir et al., 2006). In this thesis the mechanistic 
and functional aspects of the interaction between C. albicans and various 
salivary proteins, particularly salivary agglutinin and statherin, has been studied. 
 
Salivary agglutinin 
Salivary agglutinin (SAG), a high-molecular-weight glycoprotein encoded by 
the DMBT-1 gene on chromosome 10q25.3-q.26.1, is the salivary counterpart 
of gp340, which is found in lung secretions. SAG (gp340) belongs to the 
scavenger receptor cysteine-rich (SRCR) superfamily of proteins, a group of 
cell-surface and/or secreted proteins, possessing SRCR domains. SRCR proteins 
have been implicated in developmental processes or in innate immune responses. 
In addition to SRCR domains, SAG contains two CUB domains and a Zona 
Pellucida (ZP) domain (Figure 3). ZP domains are generally involved in protein 
polymerization (Jovine et al., 2005). This may also be the case for SAG which 
in saliva is present in a multimeric form (Oho et al., 1998). The SRCR domains 
are separated by SRCR interspersed domains (SIDs), which are potential O-
glycosylation sites due to their high serine/threonine content. The presence of 
numerous glycosidic side-chains on SIDS will probably force the SIDs into an 
extended stretched conformation. The polypeptide chain of the longest known 
variant of DMBT1SAG is 2313 amino acids long with a mass of 260 kDa, but on 
SDS-PAGE the molecular mass is estimated at 340 kDa, due to glycosylation 
(Issa et al., 2010; Ericson and Rundegren, 1983; Oho et al., 1998). 
 SAG interacts with a broad range of micro-organisms, including 
streptococci, Helicobacter pylori (Prakobphol et al., 2000), influenza viruses 
(Hartshorn et al., 2003) and HIV (Wu et al., 2004), but also with mucosal 
defence proteins, such as IgA (Ligtenberg et al., 2004), surfactant proteins 
(Holmskov, 1999) and MUC5B (Thornton et al., 2001). Stimulation of 
alveolar macrophage migration (Tino and Wright, 1999), suppression of 
neutrophil oxidative burst and activation of the complement system (Boackle et 
al., 1993) further point to an important role in the regulation of inflammatory 
responses. The role of SAG in the innate immune defence has been explored by 
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investigating the SAG mediated activation of the complement system (Chapter 
6). 
 SAG is one of the major bacteria-aggregating components in saliva and can 
be demonstrated on oral bacteria in situ (Issa et al., 2010). Bikker et al. (Bikker 
et al., 2002) discovered that the part of SAG responsible for the interaction with 
S. mutans was located in the SRCR domains of the protein (Bikker et al., 2004). 
A 16-mer peptide fragment of the SRCR domains (SRCRP2) could both 
adhere and aggregate S. mutans. The question was addressed whether this 
domain is responsible for the broad-spectrum bacteria-binding properties of 
SAG, by examination of its interaction with a wide variety of oral and non-oral 
bacteria (Chapter 2).  
 
Figure 3. Structure of SAG. SAG consists of 13 SRCR domains (yellow blocks) followed by 
two CUB domains that are separated by another SRCR domain and then a Zona Pellucida 
domain. Except between the SRCR domains 4 and 5 are the first 13 SRCR domains separated 
by SRCR interspersed domains (SIDs) which offer many potential glycosylation sites 
(Holmskov et al., 1999).  
 
Statherin 
Statherin is a salivary phosphopeptide of 43 amino acid residues encoded by the 
STATH gene on chromosome 4 (Sabatini et al., 1987). Statherin is structurally 
disordered in aqueous solution, but NMR assignments and structural analysis in 
50% trifluoroethanol water mixtures revealed three distinct structural motifs in 
the molecule: (1) an α-helical structure at the N-terminal domain comprising 
Asp1-Tyr16, (2) a polyproline type II (PPII) conformation predominantly 
occurring at the middle proline-rich domain spanning Gly19-Gln35, and (3) a 
310-helical structure at the C-terminal Pro36-Phe43 sequence (Naganagowda et 
al., 1998). 
CUB domainSID domain ZP domain
Transmembrane domainCarbohydrate chain
SRCR domain
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Statherin is implicated in the maintenance of tooth mineral. By binding 
calcium ions it inhibits precipitation of calcium phosphate salts and it forms a 
calcium buffer for remineralization. The negatively charged stretch 
encompassing the first five N-terminal amino acid residues (DpSpSEE) 
mediates binding of statherin to hydroxyapatite and inhibits crystal growth 
(Figure 4). The proline-rich region at the C-terminal side of the peptide has 
been implicated in binding to micro-organisms (Niemi and Johansson, 2004). 
The exact minimal binding motif, however, has yet to be identified. 
 Statherin coated onto hydroxyapatite surfaces has been shown to bind to a 
number of bacteria and fungi, including Actinomyces spp. Porphyromonas 
gingivalis, Fusobacterium nucleatum, and Candida albicans (Gibbons and Hay, 
1988; Gibbons et al., 1988; Johansson et al., 2000; Niemi and Johansson, 
2004). In chapter 4 the effect of statherin on hyphae formation of C. albicans 
has been investigated.
 
 
Figure 4. Amino acid sequence of statherin. Statherin consists of an α-helical structure at the 
N-terminal domain (Asp1 –Gly15), a middle poly-L-proline II(Gly15 – Leu29), and a β-turn at 
the C-terminal end (Leu29-Phe43). It contains two phosphoserines at position 2 and 3. 
Together with Asp1, Glu4 and Glu5 this results in a highly negatively charged N-terminus 
(Schlesinger and Hay, 1977).  
 
- - ---+ ++  + -
DpSpSEEKFLRRIGRFGYGYGPYQPVPEQPLYPQPYQPQYQQYTF
3(10)-Helix
polyproline type II
Alpha-Helix
Hydroxylapitite 
binding 
sequence
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Thesis Outline 
The aim of this thesis was to study the role of saliva on the microbial 
colonization, especially of C. albicans. Salivary agglutinin and statherin were 
identified as two salivary substances modulating the colonization of C. albicans. 
 
- In the SRCR domains of SAG the bacteria-binding site has been 
identified as the SRCRP2 peptide. This motif shows broad spectrum 
bacteria binding. In Chapter 2 was investigated whether the binding of 
this peptide to different micro-organisms correlated with the binding of 
the whole SAG molecule. By an alanine substitution scan within this 
peptide was investigated which amino acids were essential for binding to 
different bacteria. For different bacteria different binding motifs could 
be identified.  
 
- The interaction of SAG with bacteria has been subject of numerous 
studies. Far less is known, however, about its interaction with yeasts. In 
Chapter 3 the binding of salivary components to C. albicans was 
investigated. Next to SAG also statherin was shown to bind to C. 
albicans. In contrast to bacterial binding, binding of SAG to C. albicans 
was independent of Ca2+ions and not affected by reduction of SAG. 
 
- In the oral cavity C. albicans is primarily present in the less virulent yeast 
form and not in the hyphae form. In Chapter 4 the effect of saliva on 
hyphae growth of C. albicans was investigated. Saliva induces transition 
of C. albicans hyphae to the less virulent yeast form thus demonstrating 
a new salivary defence mechanism. Purification and testing of synthetic 
peptides showed that salivary statherin is responsible for this transition.  
 
- In Chapter 5 we map the domain within statherin that is responsible 
for C. albicans transition from the hyphal to the yeast form. 
 
- Although SAG in the oral cavity primarily has been described as a 
bacteria binding protein it also interacts with other immune proteins 
which suggests a role in innate immune functions. In Chapter 6 was 
investigated how SAG initiates complement activation. We show that 
Chapter 1   
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SAG induces complement activation through the lectin pathway by 
binding to mannose-binding lectin.  
 
- In Chapter 7 an overview has been given in which the topics that have 
been addressed are being discussed giving a future prospective.
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Abstract 
Salivary agglutinin (DMBT1SAG) is identical to lung glycoprotein-340 and 
encoded by Deleted in Malignant Brain Tumors-1. It is a member of the 
scavenger receptor cysteine-rich (SRCR) superfamily, proteins that have one or 
more SRCR domains. Salivary agglutinin plays a role in oral innate immunity 
by the binding and agglutination of oral streptococci. Streptococcus mutans has 
been shown to bind to a 16-mer peptide (QGRVEVLYRGSWGTVC) located 
within the SRCR domains. Within this peptide, designated SRCR peptide 2, 
amino acid residues VEVL and W were critical for binding.  
The aim of this study was to investigate binding of DMBT1SAG to other 
bacteria. Therefore, interaction between a series of bacteria and DMBT1SAG, 
SRCR peptide 2 and its alanine substitution variants was studied in adhesion 
and agglutination assays. For different bacteria there was a highly significant 
correlation between adhesion to DMBT1SAG and adhesion to SRCR peptide 2 
suggesting that SRCR peptide 2 is the major bacteria binding site. An alanine 
substitution scan showed that 8 amino acids were involved in binding 
(xRVEVLYxxSWxxxx).The binding motifs varied for different species, but the 
residues VxVxY and W were always present. In conclusion, a common binding 
motif (RVEVLYxxxSW) within the SRCR domains is responsible for the broad 
bacteria-binding spectrum of DMBT1SAG. 
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Introduction 
Salivary agglutinin is a 300-400 kDa glycosylated protein which is identical to 
lung gp-340 and DMBT1 (Deleted in Malignant Brain Tumors-1) 
((Mollenhauer et al., 1997; Holmskov et al., 1999; Prakobphol et al., 2000; 
Ligtenberg et al., 2001). These proteins are encoded by the gene DMBT1 on 
chromosome 10q25.3-q26.1. Salivary agglutinin (designated DMBT1SAG) 
belongs to the scavenger receptor cysteine-rich (SRCR) protein superfamily.  
The SRCR superfamily comprises cell-surface molecules as well as 
secreted proteins that are characterized by the presence of one or more SRCR 
domains (Resnick et al., 1994; Sarrias et al., 2004). The SRCR domain is a 
motif of about 100 amino acids with highly conserved cysteine residues. SRCR 
proteins are found in metazoan organisms along the entire animal kingdom 
((Freeman et al., 1990; Resnick et al., 1994) and in protozoan parasites such as 
Plasmodium (Claudianos et al., 2002). The SRCR superfamily is divided into 
two groups based on the number of conserved cysteine residues within the 
SRCR domains. Group A proteins contains SRCR domains with 6 conserved 
cysteine residues, group B proteins contains SRCR domains with 8 conserved 
cysteine residues (Resnick et al., 1994). DMBT1SAG belongs to the group B 
SRCR proteins ((Holmskov et al., 1997; Mollenhauer et al., 1997; Holmskov et 
al., 1999; Prakobphol et al., 2000; Ligtenberg et al., 2001). DMBT1SAG 
homologues are found in the rat (Ebnerin) (Li and Snyder, 1995), mouse 
(CRP-ductin) (Cheng et al., 1996), rabbit (Hensin) (Takito et al., 1999), and 
cow (bovine gallbladder mucin) (Nunes et al., 1995). Molecules of this 
subgroup are expressed by epithelial cells in the gastrointestinal tract and the 
ducts of the exocrine glands and are usually secreted into mucosal fluids (Bikker 
et al., 2002b). They are associated with host defence, e.g. by pathogen binding, 
but also have been suggested to play a role in epithelial differentiation 
(Mollenhauer et al., 2000). 
DMBT1SAG has been known initially for its role in caries prevention by 
binding and agglutination of cariogenic bacteria in the oral cavity (Ericson and 
Rundegren, 1983; Carlen et al., 1998). It shows calcium-dependent binding to 
antigen I/II polypeptides of Streptococcus mutans (Demuth et al., 1990). In other 
studies DMBT1SAG was shown to have a broad bacteria recognition capability 
(Prakobphol et al., 2000). By showing that DMBT1SAG is capable of inhibiting 
HIV-1 infectivity an even broader role in innate immunity was suggested (Wu 
et al., 2003). 
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For bacterial binding several carbohydrate receptor structures on 
DMBT1SAG have been identified (Demuth et al., 1990; Ligtenberg et al., 2000; 
Eriksson et al., 2007), but also a protein sequence in the SRCR domains of 
DMBT1SAG has been shown to bind to S. mutans (Bikker et al., 2002a; Bikker et 
al., 2004). The peptide derived from this protein sequence 
(QGRVEVLYRGSWGTVC) was designated SRCRP2. Binding studies on N- 
and C-terminally shifted peptides revealed that a minimal 11 amino acids 
sequence (GRVEVLYRGSW) within this SRCRP2 was essential for bacteria 
binding. An alanine-substitution-scan on this 11 amino acids sequence revealed 
that the amino acids GxVEVLxxxxW were important for binding to S. mutans 
(Bikker et al., 2004). To examine whether one and the same binding motif is 
responsible for the broad bacteria binding spectrum of DMBT1SAG, in the 
present study binding of DMBT1SAG, SRCRP2 and its alanine-substitution-
variants have been tested upon various bacterial species.  
We show that even though there are some differences in binding motifs 
between the different bacteria there is a common set of amino acids, VEVLY 
and W, which are essential for binding of all bacteria tested. 
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Materials and methods 
 
Solid phase peptide synthesis 
Peptides were synthesized by solid phase Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry using a MilliGen 9050 peptide 
synthesizer (MilliGen/Biosearch, Bedford, MA), as described previously (Bikker 
et al., 2002a). 
Peptide purification—Peptides were purified by reversed-phase HPLC on a 
JASCO HPLC System (Tokyo, Japan). Peptides were dissolved in 0.1% 
trifluoroacetic acid and applied on a VYDAC C18-column (218TP, 1.0 x 25 
cm, 10-µm particles, Vydac, Hesperia, CA) equilibrated in 0.1% trifluoroacetic 
acid. Elution was performed with a linear gradient from 20 to 45% acetonitrile 
containing 0.1% trifluoroacetic acid in 20 min at a flow rate of 4 ml/min. The 
absorbance of the column effluent was monitored at 214 nm, and peak fractions 
were pooled, lyophilized, and reanalyzed by reversed-phase-HPLC and by 
capillary electrophoresis on a Biofocus 2000 apparatus (Bio-Rad). The 
authenticity of the (monomeric) peptides was confirmed by MALDI-TOF-MS. 
For MALDI-TOF-MS, 1 volume of sample was manually mixed with 1 volume 
of matrix (2 mg of a-cyano-4-hydroxycinnamic acid in 1 ml 80% 
acetonitrile/10 mM di-ammonium citrate) in a tube from which 0.7 ml was 
deposited on a stainless steel MALDI plate. MALDI-TOF-MS was performed 
in reflectron positive mode on the 4800 MALDI-TOF/TOF mass spectrometer 
(Applied Biosystems). The acquisition laser power was set just above the 
threshold. Data acquisition was automated through the software, and 
programmed to accumulate 5000 shots per spectrum (reflectron). The 
instrument was externally calibrated using a calibration peptide mixture. The 
purity of the peptides was at least 90%. 
 
Purification of DMBT1SAG 
DMBT1SAG was purified as described previously (Ligtenberg et al., 2000). 
Twenty-five ml of human parotid saliva, collected with a Lashley cup was kept 
on ice for 30 min resulting in the formation of a precipitate. This precipitate 
was collected by centrifugation at 5,000 g for 20 min at 4 °C, and subsequently 
dissolved in 1/10 volume of TBS supplemented with 10 mM EDTA. This was 
applied on a Sephacryl S-400 (Amersham Biosciences, Roosendaal, Netherlands) 
gel filtration column (15 x 490 mm) that was run in TBS. Fractions were 
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monitored at 280 nm. DMBT1SAG migrated in the first peak fraction and purity 
was checked by SDS-PAGE and silver staining. 
 
Bacteria and growth conditions 
Experiments were conducted with S. mutans strains Ingbritt, NG8 and UA159, 
Streptococcus mitis (HG168), Streptococcus gordonii (HG222), Lactobacillus 
acidophilus (HG387), Bacillus cereus (clinical isolate), Staphylococcus aureus 
(HG386), Salmonella typhimurium (LT2) and E. coli K12. Strains were stored 
frozen in Protect bacterial preservers (Technical Service Consultants LTD, Bury, 
Lancs., U.K.) at -80 oC. For experimental purposes, bacteria were cultured on 
blood agar plates and grown for 48 h at 37 oC under aerobic conditions with 5% 
CO2. Subsequently, a colony was picked up for inoculation of Todd Hewitt 
Broth (Difco Laboratories, Detroit, Michigan, USA) for the Streptococcus 
species and of BHI for the other species. Cultures were grown overnight at 37 
oC in completely filled 100 ml flasks under aerobic conditions with 5% CO2 
without shaking. Cells were harvested by centrifugation (3,000 g for 10 min at 
22 oC), washed in TBST-Ca (10mM Tris-HCl, 150mM sodium chloride, 0.1% 
Tween 20, pH 7.5, 1mM CaCl2) and resuspended in TBST to an optical 
density at 700 nm (OD700) of 0.9 to 1.0. 
 
Adhesion assay (Solid phase binding assay) 
Bacterial adhesion was examined using a microplate method based on the 
labelling of micro-organisms with the cell-permeable DNA binding probe, 
SYTO-13 (Invitrogen, Leiden, The Netherlands) (Bosch et al., 2003). The 
peptides were dissolved in distilled water to a starting concentration of 200 
µg/ml. Hereafter, they were 1:1 serially diluted in Fluotrac-600 microplates 
(Greiner, Recklinghausen, Germany). After evaporation for 16 h at 45 °C, dried 
plates were washed with TBST and with distilled water. Subsequently, 100 µl of 
a bacterial suspension (OD700: 1,0) in TBST supplemented with 1mM CaCl2, 
was added to each well and incubated for 2 h at 37 °C. Thereafter plates were 
washed four times with TBST using a plate washer (Mikrotek EL 403, 
Winooski, VT). Bound bacteria were detected using 100 µl/well of a 1 mM 
SYTO-13 solution in TBS. Plates were incubated in the dark at 37 °C for 30 
minutes and washed three times with TBST. Fluorescence was measured in a 
Fluostar Galaxy microplate fluorescence reader (BMG Laboratories, Offenburg, 
Germany) at 488 nm excitation and 509 nm emission wavelengths. These 
experiments were repeated at least three times. To convert fluorescence signals 
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to number of bacterial cells, for each bacterial strain the number of colony 
forming unit was determined by culturing, and related to the fluorescence signal. 
 
For the competitive bacteria binding assay microplates were coated with serially 
diluted SAG preparation. After washing, microplates were incubated with 
bacterial suspensions containing 200µg/ml peptide. To examine the influence of 
the NaCl concentration on the adhesion of bacteria to SRCRP2 adhesion assays 
were performed using TBST solutions with 10, 100, 150 and 300 mM NaCl. 
Influence of pH on the bacterial adhesion to SRCRP2 was examined using 
PBST, adjusted to the appropriate pH-value. 
 
Agglutination assays 
Bacterial agglutination was studied in round-bottom microplates and confirmed 
by microscopy. 20 µl peptide solutions were serially diluted in 96-well round-
bottom microplates (Falcon, Piscataway, NJ) at final peptide concentrations of 
0–100 µg/ml. Hereafter 100 µl of bacteria suspensions in TBST-Ca was added 
and the mixture was incubated for 2 h at 37 °C. After agglutination or 
sedimentation, 5 µl was taken from the bottom of the well and transferred on a 
microscopic slide, Gram stained and examined by light microscopy (Leica 
Gmbh., Wetzlar, Germany). Agglutination activity was semi-quantified by 
scoring the lowest concentration at which the peptide was still able to 
agglutinate the bacteria completely. 
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Table 1. SRCRP2 alanine-substitution-variants 
This table shows a schematic view of the alanine in each SRCRP2-substitution-variant 
synthesized. The one-letter code is used for amino acid residues. The first column shows the 
codenames of the peptide. The second row in the table shows the base-peptide SRCRP2. The 
bold printed letters in the name of each substitution-variant depicts the residue substituted and 
its position. 
 
 
  
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
SRCRP2 Q G R V E V L Y R G S W G T V C 
SRCRP2 G2A Q A R V E V L Y R G S W G T V C 
SRCRP2 R3A Q G A V E V L Y R G S W G T V C 
SRCRP2 V4A Q G R A E V L Y R G S W G T V C 
SRCRP2 E5A Q G R V A V L Y R G S W G T V C 
SRCRP2 V6A Q G R V E A L Y R G S W G T V C 
SRCRP2 L7A Q G R V E V A Y R G S W G T V C 
SRCRP2 Y8A Q G R V E V L A R G S W G T V C 
SRCRP2 R9A Q G R V E V L Y A G S W G T V C 
SRCRP2 G10A Q G R V E V L Y R A S W G T V C 
SRCRP2 S11A Q G R V E V L Y R G A W G T V C 
SRCRP2 W12A Q G R V E V L Y R G S A G T V C 
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Results 
 
DMBT1SAG and SRCRP2 correlate for bacteria binding 
Binding of bacteria to serial dilutions of SRCRP2 was tested in the adhesion 
assay. Figure 1 shows adhesion of S. mutans UA159, S. gordonii HG222, B. 
cereus and L. acidophilus HG387 to SRCRP2 coated plates. At a peptide 
concentration of 100  g/ml there was a clear difference between strongly and 
weakly adhering bacteria.  
In the adhesion assay different bacterial strains were compared for binding to 
DMBT1SAG and the SRCRP2 peptide (Figure 2). Both DMBT1SAG and 
SRCRP2 mediated binding of all bacteria tested. No binding occurred to the 
uncoated wells. There was a highly significant positive correlation between 
adhesion to DMBT1SAG and adhesion to SRCRP2 suggesting SRCRP2 is an 
important binding site on DMBT1SAG.  
  
Binding profile based on adhesion test 
Within SRCRP2 an 11 amino acid sequence (GRVEVLYRGSW) has been 
identified as the essential binding site for S. mutans (Bikker et al., 2004). To 
investigate to which extent each of the eleven amino acids contributes to 
bacterial adhesion, an alanine substitution scan was performed in which each 
amino acid across the 11 amino acid sequence consecutively was substituted by 
an alanine (Table 1). These peptides together with the original SRCRP2 were 
tested in the adhesion assay upon binding of each bacterium species (Figure 3). 
The binding profiles resulting from the adhesion assays show that there 
is a similar trend for all the bacteria. The alanine substitutions from position 3 
to 8 (RVEVLY) led to a substantial decrease in the adhesion of most bacteria. 
Also alanine substitution of W12 almost completely abolished the adhesion of 
all bacteria species tested. Replacement of glutamic acid at position 5 by alanine 
strongly decreased binding of streptococci, but only had a small effect on the 
binding to S. aureus, B. cereus and E. coli. Substitution of the two glycines, at 
position 2 and 10 leads in most cases to an increased bacterial adhesion.  
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Fig. 1. Bacterial adhesion to SRCRP2 
Microplates coated with SRCRP2 peptide were incubated with suspensions of bacteria. Bound 
bacteria were detected with a cell-permeable DNA binding fluorescent dye (syto13) and 
subsequently the fluorescent signal was converted in bacteria numbers. Bacteria showed large 
variation in adhesion. These experiments were performed with all the bacteria, at least in 
triplicate. 
 
Competition assay 
To examine whether SRCRP2 was able to inhibit bacteria binding to 
DMBT1SAG a competition assay was performed with S. mutans and L. 
acidophilus. Microplates were coated with DMBT1SAG and incubated with 
bacteria in the presence of SRCRP2 or DMBT1SAG. Adhesion of bacteria to 
SAG coated plates was used as a control and set at 100%. Just like DMBT1SAG, 
SRCRP2 inhibited the binding to DMBT1SAG-coated microplates suggesting 
this peptide fragment is an important bacteria binding site (Figure 4). 
In addition, to investigate whether for competitive inhibition the same residues 
were critical as for adhesion the alanine substitution variants of SRCRP2 were 
also tested for inhibition. The profiles obtained (Figure 4) revealed the same 
trend as was found in the direct binding assays, i.e. substitution of residues 2 
and 10 had little if any effect, while substitution of 5,6,7 and 8 abolished 
inhibition almost completely. 
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Fig. 2. Correlation between DMBT1SAG and SRCRP2 for adhesion of several bacteria. 
SRCRP2 or purified DMBT1SAG were immobilized onto microplate wells and tested for 
bacterial binding in the adhesion-assay. The X-axis shows the number of bacteria bound to the 
DMBT1SAG coated wells and the Y-axis shows number of bacteria bound to the SRCRP2 coated 
wells. Statistical analysis was done with SPSS, using a 2-tailed Spearman rank test to calculate 
the correlation coefficient. The correlation coefficient was 0,964 with a significance level of 
0,0005 and a linear r2 of 0,932. 
 
Bacteria agglutinating properties 
In addition, the bacteria-binding properties of SRCRP2 and its alanine 
substitution variants were also tested in the soluble phase, by monitoring 
bacteria agglutination properties (Figure 5). Agglutination was analyzed visually 
and microscopically (Figure 5). When no agglutination occurred bacteria 
formed a white pellet in the centre of the round-bottom well (Figure 5-A2) and 
microscopically bacteria were homogeneously dispersed (Figure 5-A1). When 
complete agglutination occurred a film of bacteria was formed covering the 
whole bottom of the well (Figure 5-B2) and microscopically large solid 
aggregates were visible (Figure 5-B1). When incomplete agglutination occurred, 
a faint white pellet as well as a film could be detected in the well (Figure 5-C2) 
and microscopically a mixture of the aforementioned microscopic images was 
visible (Figure 5-C1).  
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B. cereus, L. acidophilus and E. coli K12 showed auto-agglutination. S. 
typhimurium and S. aureus showed no agglutination with SRCRP2 or 
DMBT1SAG. For the other bacterial strains DMBT1SAG and SRCRP2 clearly 
induced agglutination, highlighting the bacteria-peptide interaction in the 
soluble phase. Agglutination was quantified by scoring the lowest agglutinating 
peptide concentration (Table 2). This revealed that, with the exception of Arg-3, 
all residues that were critical for peptide mediated bacterial adhesion (Figure 2) 
were also involved in the peptide-mediated agglutination.  
  
 
Table 2. Minimal agglutination titre of SRCRP2 and the SRCRP2 alanine-substitution-
variants against different bacteria 
Bacteria were mixed with serial dilutions of peptides in microplates (200  g/ml starting 
concentration). After 2 hours of incubation the agglutination was scored. The agglutination 
titre (in  g/ml) was defined as the highest dilution at which complete agglutination was 
detectable visually and by microscopy. A score of “0” was given when no agglutination was 
detected.  
 
Influence of the electrostatic interactions on bacterial adhesion 
To explore the involvement of electrostatic interactions on the binding of 
bacteria to DMBT1SAG, we examined the effect of ionic strength and pH on the 
adhesion of bacteria to DMBT1SAG-coated microplates. This revealed that 
variation in ionic strength did not influence the adhesion of L. acidophilus and 
E. coli (Table 3). The adhesion of S. mutans showed a small increase of 
approximately 20%, when the NaCl concentration was lowered from 300 mM 
to 10 mM, suggesting that electrostatic interactions to some extent play a role in 
the adhesion of this species to DMBT1SAG. Varying the pH between 4.0 and 9.0 
did not influence the binding of L. acidophilus or E. coli (Figure 6). Between pH 
6.0 and 9.0 the adhesion of S. mutans was neither affected. However, lowering 
the pH from 6.0 to 4.0 resulted in an almost two-fold higher adhesion. Taken 
Gram Bacterium P2 G2A R3A V4A E5A V6A L7A Y8A R9A G10A S11A W12A
                            
+ S. mutans UA159 100 50 100 0 0 0 0 0 100 50 200 0 
+ S. mutans Ingbritt 100 50 100 0 0 0 0 0 100 25 0 0 
+ S. mjutans NG8 100 100 0 0 0 0 0 0 0 100 0 0 
+ S. gordonii HG222 100 100 200 0 200 0 200 0 0 100 200 0 
+ S. mitis HG168 100 100 200 0 0 0 0 0 0 100 0 0 
+ S. aureus HG386 0 0 0 0 0 0 0 0 0 0 0 0 
- S. typhimurium LT2  0 0 0 0 0 0 0 0 0 0 0 0 
+ B. cereus     Auto-agglutination 
+ L. acidophilus HG387     Auto-agglutination 
- E.coli K12     Auto-agglutination 
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together these experiments suggest that electrostatic interactions play only a 
minor role in the adhesion to DMBT1SAG.  
 
 
 
 
 
 
 
 
 
Table 3 Influence of the NaCl concentration on the adhesion of three bacteria to 
SRCRP2 coated plates.  
Bacteria resuspensded in TBST with adjusted NaCl concentration were incubated in wells 
coated with 100 µg/ml SRCRP2 peptide. The number of bound cells was determined as 
described in the adhesion assay. These experiments were performed at least in triplicate. 
 
 
 
 
 
 Number of bacteria bound (x106) 
[NaCl]  S. mutans L. acidophilus E.coli 
10   mM  27.60 ± 0.67 12.09 ± 0.24 1.61 ± 0.28 
100 mM  23.71 ± 0.47 12.15 ± 0.36 1.84 ± 0.13 
150 mM  22.90 ± 0.74 11.92 ± 0.48 1.85 ± 0.13 
300 mM  21.03 ± 1.00 11.31 ± 0.16 1.82 ± 0.08 
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Figure 3. Adhesion profile of SRCRP2 peptides and alanine-substitution-variants for 
different bacteria 
Bacteria were incubated in wells coated with 100 µg/ml of the various peptides, in the presence 
of the cell-permeable DNA probe SYTO-13. After washing, fluorescence was determined. For 
each peptide, binding is presented relative to that of the standard peptide SRCRP2 (set at 
100%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  4. Competitive bacteria binding assay with peptide to DMBT1SAG coated 
microplates. The bacterial adhesion to SAG coated microplates was measured in the presence 
of peptides and compared to adhesion in buffer (100 %). As a control DMBT1SAG was added to 
the bacteria suspension to compete with the surface coated DMBT1SAG. The Y-axis shows the 
relative binding percentage. Peptides with high binding affinity for the bacteria were able to 
inhibit binding of the bacterium to the DMBT1SAG coated plates resulting in a low binding 
percentage. 
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Fig. 5. Micro- and macroscopic picture of DMBT1SAG induced bacterial agglutination. 
DMBT1SAG solution was mixed with suspension of S. mutans UA159 in a round-bottom micro-
plate as described in Materials and Methods. After 2 hours a sample was taken and after Gram 
staining examined by light microscopy.  
Agglutination was detected by Gram-staining (A1, B1, C1) and a visual examination (A2, B2, 
C2). Agglutination was visible in two forms, complete agglutination B and, incomplete 
agglutination C. In Figure B1 large solid aggregates are visible whereas in C1 less solid 
aggregates were visible. In the negative control A the bacteria were homogeneously dispersed.  
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Discussion 
In a previous study the binding domain of DMBT1SAG for S. mutans was 
identified as a 16-mer peptide within the SRCR domains (SRCRP2) (Bikker et 
al., 2002a). In the present study a series of bacteria species was tested for 
binding to DMBT1SAG and SRCRP2. A good correlation was found between 
binding to DMBT1SAG and binding to SRCRP2 suggesting this peptide motif is 
the major binding site of DMBT1SAG. Based on the adhesion assay the bacteria 
could be divided into two groups; bacteria with high affinity for SRCRP2 and 
DMBT1SAG and bacteria with low affinity for SRCRP2 and DMBT1SAG 
(Figure1). All the S. mutans strains, S. gordonii and L. acidophilus did bind to 
SRCRP2 substantially better than S. typhimurium, S. aureus and B. cereus. Both 
S. mutans and S. gordonii contain antigen I/II polypeptides on the cell surface 
which have been described for the binding of DMBT1SAG (Jenkinson and 
Demuth, 1997). L. acidophilus, however, does not possess antigen I/II 
polypeptides suggesting another surface component on these bacteria is 
responsible for binding. 
 
 
 
Fig. 6. Influence of the pH on the adhesion of three bacteria to SRCRP2 coated plates. 
Bacteria adhesion to SRCRP2 coated microplate wells was tested at different pH using pH 
adjusted PBST. The bacteria tested included S. mutans (♦) , L.acidophilus (■) and E. coli (▲). 
Bacteria numbers were determined as described in the adhesion assay. This experiment has been 
repeated three times. 
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Within SRCRP2 a minimal S. mutans binding motif of 11 amino acids 
has been identified in which five residues are essential (xxVEVLxxxxW) (Bikker 
et al., 2004). In this paper the minimal binding domain for a number of other 
bacteria, including oral streptococci, S. aureus, S. typhimurium, E. coli, B. cereus, 
L. acidophilus, was identified by alanine substitution. Within the SRCRP2 
peptide different bacteria-specific motifs were identified, but they all had 4 
hydrophobic amino acids, V4, V6, Y8 and W12, in common suggesting 
hydrophobic interactions play a role in binding to the various bacteria species. 
Also the finding that adhesion of L. acidophilus and E. coli is independent of the 
pH and salt concentration is in line with these results. Still, substitution of these 
residues by alanine only slightly decreases the overall hydrophobicity, but has a 
profound effect on the bacteria-binding properties of the resulting variant 
peptide. This suggests that the interaction requires the presence of specific 
molecular structures, and is not merely a product of non-specific hydrophobic 
interactions. Depending on the bacterial species involved, additional residues 
are required. For instance, the interaction with all streptococci was drastically 
diminished when glutamic acid on position 5 was replaced by alanine. This 
suggests the involvement of electrostatic interactions, which is supported by the 
result that S. mutans adhesion to SRCRP2 is pH and salt dependent. This 
substitution had less drastic effects on the binding to E. coli which binds 
independently of the pH and ionic strength of the solution. 
 Surprisingly the substitution of the glycine by an alanine in the majority 
of cases improved the adhesion as well as the agglutination of the bacteria. In 
addition, substitution of an arginine at position 9 by alanine did not reduce 
binding whereas a substitution by glycine did (data not shown). Glycine 
residues generate random coil structures which are more flexible than the helix 
structures that are both generated by arginine and alanine. This suggests that 
reduction of conformational flexibility also influences the peptide bacteria 
interaction. According to the peptide helix prediction program AGADIR(EMBL) 
the G10A substitution enhanced the helix content thus possibly favouring the 
binding conformation of the peptide and an R9G substitution reduced the helix 
content resulting in reduced binding. These predictions suggest that not only 
the hydrophobicity but also the conformation of the peptide plays an important 
role in binding. 
The agglutination assay with the alanine substitution variants generally 
confirmed the results of the adhesion assay. Only substitution of arginine at 
position 3, which resulted in a strong decrease in adhesion, showed much less 
effect on bacterial agglutination. Differences in binding of oral streptococci to 
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soluble phase and solid phase DMBT1SAG have been described previously 
(Loimaranta et al., 2005). This is the first study showing that SAG derived 
peptides show differences in interaction depending on whether they are fluid 
phase or surface bound.  
SRCR domains have been implicated in a number of other ligand 
binding interactions, e.g. the binding of CD6 to activated leukocyte cell 
adhesion molecule (ALCAM), and the binding of MARCO and Spα to bacteria 
(Bowen et al., 2000; Brannstrom et al., 2002; Sarrias et al., 2005). Interestingly, 
the SRCR domain of Spα contains different subdomains for LTA, and LPS, 
which are the ligands for Spα on Gram-positive and Gram-negative bacteria 
(Sarrias et al., 2005). 
In conclusion, the SRCR domains of DMBT1SAG are important binding 
sites for bacteria. A core motif of four hydrophobic amino acids (V-4, V-6, Y-8 
and W-12) in the SRCRP2 peptide is involved in binding to a wide series of 
bacteria. Other residues (R3, E-5, L-7 and S-11) may have some effect on the 
binding depending on the bacterial species tested. 
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Abstract 
Salivary agglutinin (SAG), a member of the scavenger receptor cysteine-rich 
(SRCR) superfamily, is an antimicrobial protein found in human saliva. It plays 
a role in the innate immune defence of the oral mucosa by binding calcium-
dependently to bacteria through its SRCR domains. Candida albicans is an 
opportunistic pathogen causing infections in immunocompromised people, 
xerostomia patients and denture wearers. Subject of this study is the interaction 
of SAG with C. albicans. Binding of SAG was studied by an in solution assay 
combined with immunoblotting, agglutination assays and adhesion assays to 
SAG-coated microtiterplates. In contrast to the binding of SAG to bacteria, 
which disappeared after chemical reduction of SAG, no effect on its binding to 
C. albicans was observed. Purified SAG agglutinated C. albicans in a Ca2+-
dependent manner. Ca2+-ions could be replaced by Zn2+-ions, but not by Mg2+- 
or Ba2+-ions. Unlike bacterial adhesion C. albicans adhesion to SAG-coated 
microplates was not Ca2+-dependent. These results suggest that the 
characteristics of SAG binding to C. albicans are different from SAG binding to 
bacteria. 
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Introduction 
Salivary agglutinin (SAG) is a 300-400 kDa glycosylated protein. Its protein 
sequence is identical to lung gp-340 and DMBT1 (Deleted in Malignant Brain 
Tumors-1) (Mollenhauer et al., 1997; Holmskov et al., 1999; Prakobphol et al., 
2000; Ligtenberg et al., 2001). SAG belongs to the scavenger receptor cysteine-
rich (SRCR) protein superfamily, a group of proteins containing SRCR 
domains which is primarily involved in host defence processes. SAG was 
initially found to agglutinate the cariogenic Streptococcus mutans upon which the 
bacteria are cleared from the oral cavity by swallowing. Later studies 
demonstrated that SAG binds to a wide variety of microbial species, including 
Lactobacillus spp., Streptococcus spp., Helicobacter pylori, and viruses among 
which influenza viruses and HIV (Bikker et al., 2002; Hartshorn et al., 2003; 
Wu et al., 2003; Leito et al., 2008). SAG is believed to play an important role in 
the modulation of oral bacterial colonization through its broad binding 
spectrum and its capacity to agglutinate bacteria (Ligtenberg et al., 2007).  
C. albicans colonizes a variety of body locations, notably the oral cavity, 
genitalia and gastrointestinal tract as a benign commensal (Soll, 2002). In 
healthy individuals C. albicans does not cause infectious disease or discomfort. 
However, in immunocompromised individuals, individuals with impaired saliva 
function or denture wearers outgrowth of C. albicans frequently occurs.  
In this study we describe a first step in characterizing the interaction between 
SAG and C. albicans. 
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Materials and Methods 
 
Collection of saliva and purification of SAG 
Parotid saliva from a healthy masculine donor (aged 45) was collected with a 
Lashley cup under stimulation by chewing on menthol chewing gum. SAG was 
purified as previously described (Ligtenberg et al., 2000). 25 ml of human 
parotid saliva was kept on ice for 30 min, resulting in the formation of a 
precipitate. This precipitate was isolated from the saliva by centrifugation at 
5,000 g for 20 min at 4 °C. The pellet was dissolved in 2.5 ml TBS (10 mM 
Tris, 140 mM NaCl, pH 7.4) supplemented with 10 mM EDTA, applied to a 
Sephacryl S-400 (Amersham Biosciences, Roosendaal, Netherlands) gel 
filtration column (1.6 x 50 cm) and eluted with TBS. Fractions were monitored 
at 280 nm. SAG migrated in the first peak fraction and purity was checked by 
SDS-PAGE using silver staining.  
 
Chemical reduction of parotid saliva and SAG  
Parotid saliva and 80 µg/ml SAG were reduced chemically by incubation with 
50 mM TCEP-HCl (Tris(2-carboxyethyl) phosphine hydrochloride) (Pierce, 
Rockford IL, USA) for 30 min at 37 oC, according to the manufacturers 
protocol. Reduction was verified by ELISA and Western blotting using anti-
SAG monoclonal antibody 213-06 (Antibodyshop, Gentofte, Denmark) which 
only recognizes unreduced SAG. 
 
Strain and culture conditions  
C. albicans 315 (ATCC 10231) was cultured aerobically at 30 °C on Sabouraud 
dextrose agar plates. From the agar plates a colony was picked up and 
inoculated in Sabouraud dextrose broth (pH 5.6) and cultured overnight at 
30 °C under shaking conditions to stationary phase.  
 
In-solution binding assay 
C. albicans suspension (containing 1×107 cells) was centrifuged (3,000 x g at 22 
ºC for 5 min) and resuspended in 120 µl of either parotid saliva or SAG 
solution in saliva-buffer (2 mM potassium phosphate, 50 mM KCl, 1 mM 
CaCl2 and 0.1 mM MgCl2, pH 7.2). After incubation for 1 hour at 37 °C cells 
were harvested by centrifugation and washed twice in saliva-buffer. Next the 
cells were transported into a new vial and incubated in 120 µl TBS containing 2% 
SDS at 50 oC for 10 min for extraction yeast-bound material.  
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SDS-PAGE  and immunoblotting  
Electrophoresis was performed on NuPAGE 4-12% BIS/TRIS gels (Invitrogen, 
Carlsbad CA, USA). Samples were prepared by boiling for 5 min in NuPAGE 
LDS sample buffer (Invitrogen). After electrophoresis proteins were transferred 
onto nitrocellulose membranes by semi-dry blotting using an iblot gel transfer 
system (Invitrogen). After transfer, membranes were blocked by incubation in 
PBS-Tween 20 supplemented with 2 % bovine serum albumin (PBST-BSA). 
All subsequent incubations were performed for 1 h at room temperature in 
PBST-BSA.  After each incubation, membranes were washed three times with 
PBST. Membranes were incubated with mouse monoclonal antibody 213-06 
against  SAG (Antibodyshop, Denmark) or biotinylated fucose-binding lectin 
UEA-1 (Pierce, Rockford, Il., USA). Bound 213-06 was detected with alkaline 
phosphatase (AP) conjugated rabbit anti-mouse antibody (Dako, Glostrup, 
Denmark). Biotinylated UEA-1 lectin was detected with AP-conjugated 
streptavidin (Dako).  5-bromo-4-chloro-3-indolylphosphate (Roche 
Diagnostics, Mannheim, Germany) was used as a substrate.  
 
Agglutination assays 
C. albicans agglutination by SAG was studied in round-bottom microplates 
(Falcon, Piscataway, NJ, USA). 20 µl purified SAG (50 µg/ml) was added to 
100 µl C. albicans suspension (approximately  1 × 107 cells/ml) in TBST (TBS + 
0.1% Tween 20). As a negative control 20 µl of TBS was used instead of 
purified SAG. After 1 h incubation at 30 °C agglutination was determined by 
macroscopic and microscopic examination as described previously (Leito et al., 
2008). 
 
Adhesion assay 
Adhesion assays were performed as described previously (Leito et al., 2008). 
Shortly, C. albicans was cultured over night in Sabouraud dextrose broth.  Cells 
were harvested by centrifugation (3,000 x g at room temperature for 5 min), 
washed twice in TBST and suspended in TBST-Ca (TBST supplemented with 
2.5 mM CaCl2) to a density of 1 x 107 cells/ml. Fluotrac 600 microplates 
(Greiner Bio One, Netherlands) were coated by overnight incubation with 10 
µg/ml SAG in 0.1 mM sodium carbonate pH 9.6 at 4 oC. After coating, plates 
were washed twice with TBST and once with water. Subsequently, 100 µl of C. 
albicans suspension (1×107 cells/ ml) in TBST-Ca was added to each well and 
incubated at 37 ºC for 2 h. After washing 100 µl of  the cell-permeant nucleic 
Chapter 3   
54 
 
acid stain SYTO-13 (1 mM in TBS)  (Invitrogen) was added to each well. 
Plates were incubated in the dark at 37 ºC for 1 hour and washed three times 
with TBST. Fluorescence was measured in a Fluostar Galaxy microplate 
fluorescence reader (BMG Laboratories, Offenburg, Germany) at 488 nm 
excitation and 509 nm emission wavelengths. 
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Results 
 
Binding of purified SAG to C. albicans  
The binding of SAG in parotid saliva and purified SAG to C. albicans was 
tested by an in-solution binding assay. Western blot analysis revealed that SAG 
in parotid saliva (Fig. 1A) and purified SAG (Fig. 1B) bound to C. albicans. 
Also after reduction SAG in parotid saliva and purified SAG still bound to C. 
albicans (Fig.2).   
 
 
1 2 3M
PAR SAG
1 2 3M
250kDa 250kDa
 
 
Fig. 1. Binding of SAG to C. albicans. Parotid saliva (PAR) and purified SAG (SAG) were 
incubated with C. albicans. Cell-bound components were extracted with 2% SDS and analyzed 
by Western blot using anti-SAG mAb 213-06. (1) Starting material, (2) starting material after 
incubation with C. albicans, and (3) SDS extract of C. albicans after incubation were analyzed 
by SDS-PAGE and Western blot with anti-SAG.  
 
Agglutination of C. albicans by SAG 
Both the calcium dependence and the calcium specificity of SAG-C. albicans 
agglutination was tested in microplates. SAG mediated agglutination of C. 
albicans in buffer with Ca2+ ions but not in buffer with  EGTA, a chelating 
agens for Ca2+-ions (Fig. 3A). Ca2+-ions could be replaced by Zn2+-ions, but not 
by Ba2+- or Mg2+-ions. Calcium dependent agglutination of C. albicans by SAG 
was confirmed by microscopical observation. SAG clearly induced agglutination 
in buffer with calcium ions, but not in buffer with EDTA, a chelating agent for 
divalent ions (Fig. 3B).  
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Fig. 2 Effect of chemical reduction of SAG on binding to C. albicans  
Parotid saliva (PAR) and purified SAG (SAG) were reduced using TCEP and hereafter 
incubated with C. albicans. Cell bound SAG was extracted with 2% SDS. Samples were 
analyzed by Western blotting using fucose-binding lectin UEA-1. (1), starting material; (2), 
starting material after reduction with TCEP; (3), unbound components after incubation with 
C. albicans; (4), extract from C. albicans cell surface after incubation.  
 
Adhesion of C. albicans to SAG-coated surfaces 
C. albicans was also tested for adhesion to SAG-coated microplates (Fig. 4). 
Calcium dependence was tested by either adding CaCl2 or EDTA to the C. 
albicans suspension. In contrast to SAG-mediated agglutination the adhesion of 
C. albicans to SAG was not significantly altered by either chelation of calcium 
ions by EDTA, or by the addition of extra Ca2+ ions (Fig. 4). To investigate the 
influence of pH on the interaction between C. albicans and SAG, adhesion was 
performed with C. albicans suspensions prepared in pH-adjusted PBS at pH 4, 
5, 6, 7, 8, or 9.  C. albicans adhesion to SAG increased with pH from pH 6 to 
pH 9 (Fig. 5 ). 
 
  
 
Fig. 3A. Effect of divalent cations on SAG-
C. albicans was incubated with 5 µg/ml SAG in TBS in the absence or presence of 2.5mM 
EGTA, CaCl2, BaCl2, ZnCl2 or MgCl2. As a control 
buffers without SAG. After 1 h of incubation agglutination was visually examined. Aggregates 
formed were present as a thin film covering the bottom of the wells. Non
cells sedimented as a white spot in the center of the well. Ca
mediated agglutination of C. albicans whereas EGTA, Ba
Fig. 3B. Microscopic view of C. albicans agglutination and the effect of Ca
was mixed with C. albicans suspension in saliva buffer with CaCl
EDTA. The control consisted of only saliva buffer. After 1 h samples were examined by phase
contrast microscopy. SAG caused the formation of large aggregates. When EDTA was added no 
aggregates were visible. The control showed no 
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induced agglutination of C. albicans. 
C. albicans was mixed with the same 
-agglutinating yeast 
2+- and Zn2+-ions enhanced SAG 
2+- and Mg2+-ions did not.  
2+- ions. SAG 
2 and saliva buffer with 5 mM 
-
C. albicans agglutination.  
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Fig. 4. Effect of calcium ions on the adhesion of C. albicans yeasts to SAG. 
C. albicans yeast suspension in saliva buffer, saliva buffer with 2.5 mM CaCl2 and saliva buffer 
with 2.5 mM EDTA was tested for adhesion to 3 µg/ml SAG-coated microplates. Each data 
point represents the mean of nine samples. Error bars represent the SEM.  
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Fig.5.  pH dependence of C. albicans adhesion to SAG.  
Microplates coated with approximately 10 µg/ml SAG were incubated with C. albicans yeast 
suspension for 2 h at 37 ºC using PBS of pH 4, 5, 6, 7, 8 and 9. After washing bound C. 
albicans cells were fluorescently labeled with SYTO-13 and fluorescence was measured. Results 
represent mean and SD (error bars) of three experiments.  
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Discussion 
The aim of this study was to characterize the interaction between SAG and C. 
albicans. In addition to SAG in parotid saliva also purified SAG bound to C. 
albicans (Fig. 1). It has been reported that a complex of SAG and IgA bound to 
S. mutans (Oho et al., 1998). Our results show that SAG binding to C. albicans 
is not depending on interaction with other proteins such as IgA.   
The reduction of SAG did not interfere with SAG binding to C. albicans 
(Fig. 2). SAG binding  to S. mutans and other bacteria, on the other hand, is 
sensitive for reduction (Oho et al., 1998; Ligtenberg et al., 2000). Bikker et al., 
(Bikker et al., 2002) showed that a greater part of the bacteria studied bind to 
the SRCR domains, which contain 4 disulfide bridges. Binding is therefore 
sensitive to chemical reduction. C. albicans probably recognizes other binding 
sites on SAG. Other possible binding sites on SAG are the carbohydrate 
moieties, which have been demonstrated to bind to influenza viruses and H. 
pylori (Issa et al. 2010; Hartshorn et al., 2003; Prakobphol et al., 2005).   
 We found that, similar to SAG-mediated agglutination of bacteria 
(Ligtenberg et al., 2000; Bikker et al., 2004; Leito et al., 2008), SAG-mediated 
agglutination of C. albicans was Ca2+-dependent. Ca2+-dependent binding to 
SAG has also been demonstrated for bacteria, IgA and surfactant protein D 
(Ericson and Rundegren, 1983; Holmskov, 1999; Ligtenberg et al., 2000; 
Hartshorn et al., 2006). Ca2+-ions are often involved in bridging between two 
negatively charged surfaces. This function can be taken over by other divalent 
ions. Of the other ions tested, Zn2+-ions could substitute for Ca2+-, but Mg2+- or 
Ba2+-ions could not, suggesting that the effect involves a specific binding of 
Ca2+- or Zn2+-ions to either the protein or the yeast. In contrast, adhesion of C. 
albicans to SAG immobilized to polystyrene, occurred also in the absence of 
calcium in contrast to bacterial adhesion to SAG (Ligtenberg et al., 2000). This 
also adds up to the suggestion that the C. albicans binding site of SAG is 
different from the bacteria binding site. 
In conclusion, these results show that the mode of SAG binding to C. 
albicans is different from SAG binding to bacteria. Future research has to reveal 
the exact mechanism of SAG binding and the role in colonization of C. albicans.  
 
Chapter 3   
60 
 
References 
Bikker FJ, Ligtenberg AJM, End C, Renner M, Blaich S, Lyer S, Wittig R, van't 
Hof W, Veerman ECI, Nazmi K, de Blieck-Hogervorst JM, Kioschis P, 
Nieuw Amerongen AV, Poustka A, Mollenhauer J. 2004. Bacteria 
binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW 
motif in its scavenger receptor cysteine-rich domains. J Biol Chem 
279:47699-47703. 
Bikker FJ, Ligtenberg AJM, Nazmi K, Veerman ECI, van't Hof W, Bolscher 
JGM, Poustka A, Nieuw Amerongen AV, Mollenhauer J. 2002. 
Identification of the bacteria-binding peptide domain on salivary 
agglutinin (gp-340/DMBT1), a member of the scavenger receptor 
cysteine-rich superfamily. Journal of Biological Chemistry 277:32109-
32115. 
Ericson T, Rundegren J. 1983. Characterization of a salivary agglutinin reacting 
with a serotype c strain of Streptococcus mutans. Eur J Biochem 133:255-
261. 
Hartshorn KL, Ligtenberg A, White MR, Van Eijk M, Hartshorn M, 
Pemberton L, Holmskov U, Crouch E. 2006. Salivary agglutinin and 
lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-
influenza activities and interactions with surfactant protein D that vary 
according to donor source and sialylation. Biochem J 393:545-553. 
Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. 
2003. Lung and salivary scavenger receptor glycoprotein-340 contribute 
to the host defense against influenza A viruses. Am J Physiol Lung Cell 
Mol Physiol 285:L1066-1076. 
Holmskov U. 1999. Lung surfactant proteins (SP-A and SP-D) in non-adaptive 
host responses to infection. J Leukoc Biol 66:747-752. 
Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, Kliem 
A, Reid KBM, Poustka A, Skjodt K. 1999. Cloning of gp-340, a 
putative opsonin receptor for lung surfactant protein D. Proceedings of 
the National Academy of Sciences of the United States of America 
96:10794-10799. 
Issa S, Moran AP, Ustinov SN, Lin JH, Ligtenberg AJM, Karlsson NG. 2010. 
O-linked oligosaccharides from salivary agglutinin: Helicobacter pylori 
  Interaction between SAG and C. albicans 
61 
 
binding sialyl-Lewis x and Lewis b are terminating moieties on 
hyperfucosylated oligo-N-acetyllactosamine. Glycobiology 20:1046-
1057. 
Leito JTD, Ligtenberg AJM, Nazmi K, de Blieck-Hogervorst JM, Veerman ECI, 
Nieuw Amerongen AV. 2008. A common binding motif for various 
bacteria of the bacteria-binding peptide SRCRP2 of DMBT1/gp-
340/salivary agglutinin. Biol Chem 389:1193-1200. 
Ligtenberg AJM, Veerman ECI, Nieuw Amerongen AV. 2000. A role for Lewis 
a antigens on salivary agglutinin in binding to Streptococcus mutans. 
Antonie Van Leeuwenhoek 77:21-30. 
Ligtenberg AJM, Veerman ECI, Nieuw Amerongen AV, Mollenhauer J. 2007. 
Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with 
variable composition and with different functions in infection, 
inflammation and cancer. Biol Chem 388:1275-1289. 
Ligtenberg TJM, Bikker FJ, Groenink J, Tornoe I, Leth-Larsen R, Veerman 
ECI, Nieuw Amerongen AV, Holmskov U. 2001. Human salivary 
agglutinin binds to lung surfactant protein-D and is identical with 
scavenger receptor protein gp-340. Biochemical Journal 359:243-248. 
Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, von Deimling A, 
Poustka A. 1997. DMBT1, a new member of the SRCR superfamily, is 
deleted in malignant brain tumors. American Journal of Human 
Genetics 61:A75-A75. 
Oho T, Yu H, Yamashita Y, Koga T. 1998. Binding of salivary glycoprotein-
secretory immunoglobulin A complex to the surface protein antigen of 
Streptococcus mutans. Infect Immun 66:115-121. 
Prakobphol A, Boren T, Ma W, Zhixiang P, Fisher SJ. 2005. Highly 
glycosylated human salivary molecules present oligosaccharides that 
mediate adhesion of leukocytes and Helicobacter pylori. Biochemistry 
44:2216-2224. 
Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, 
Frangsmyr L, Holmskov U, Leffler H, Nilsson C, Boren T, Wright JR, 
Stromberg N, Fisher SJ. 2000. Salivary agglutinin, which binds 
Streptococcus mutans and Helicobacter pylori, is the lung scavenger 
receptor cysteine-rich protein gp-340. Journal of Biological Chemistry 
275:39860-39866. 
Chapter 3   
62 
 
Soll DR. 2002. Candida commensalism and virulence: the evolution of 
phenotypic plasticity. Acta Trop 81:101-110. 
Wu ZW, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, Malamud 
D. 2003. Salivary agglutinin inhibits HIV type 1 infectivity through 
interaction with viral glycoprotein 120. Aids Research and Human 
Retroviruses 19:201-209. 
 
  
CHAPTER 4 
 
Identification of salivary components that induce 
transition of hyphae to yeast in Candida albicans 
 
 
 
Jelani T.D. Leito*, Antoon J. M. Ligtenberg, Kamran Nazmi, Enno C. I. 
Veerman 
 
 
 
FEMS Yeast Res.  9(2009)1102-1110 
 
Chapter 4   
64 
 
Abstract 
Candida albicans, the major human fungal pathogen, undergoes a reversible 
morphological transition from single yeast cells to pseudohyphae and hyphae 
filaments. The hyphae form is considered to be the most invasive form of the 
fungus. The purpose of this study is to investigate the effect of whole saliva and 
parotid saliva on hyphae growth of C. albicans. 
C. albicans hyphae were inoculated in RPMI medium with whole saliva, parotid 
saliva or buffer mimicking the saliva ion composition and cultured 18 hours at 
37 ºC under aerobic conditions with 5% CO2. Whole saliva and parotid saliva 
induced transition to yeast growth whereas the culture with buffer remained in 
the hyphae form. Parotid saliva was fractionated on a reverse phase C8 column 
and each fraction was tested for inducing transition to yeast growth. By 
immunoblotting the salivary component in the active fraction was identified as 
statherin, a phosphoprotein of 43 amino acids that has been implicated in 
remineralization of the tooth surface. Synthetically made statherin induced 
transition of candidacidal hyphae form to the yeast form. By deletion of 5 
amino acids at the negatively charged N-terminal site (DpSpSEE) the yeast 
form of C. albicans and the binding to C. albicans was increased. In conclusion, 
statherin induces transition to yeast of C. albicans hyphae and thus may 
contribute to the oral defence against candidiasis.  
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Introduction 
The most common systemic fungal infection is candidiasis, which accounts for 
well over half of the invasive mycoses. A single species, Candida albicans, causes 
the majority of these infections. Its success stems in part from its capacity to live 
as a benign commensal in a variety of body locations, notably the oral cavity, 
genitalia, and gastrointestinal tract (Soll, 2002). It causes infectious disease in 
case the host is immunocompromised. An important feature of C. albicans, 
relevant to its pathogenesis, is its ability to switch between different 
morphological forms. C. albicans can grow in a single-celled, budding yeast 
form (blastospore or blastoconidia) or in a filamentous form, including both 
pseudohyphae and true hyphae (Berman, 2006). While yeasts are important for 
dissemination within the host, hyphae are essential for outgrowth and biofilm 
formation (Lo et al., 1997; Bastidas and Heitman, 2009). Typically C. albicans 
grows in the budding yeast form but under influence of a number of 
environmental signals, such as osmotic shock, alterations of temperature, pH 
and nutrients, it can switch to the filamentous form (Buffo et al., 1984). The 
hyphae form is often considered to be the essentially virulent form of the yeast 
(Zheng et al., 2004; Bastidas and Heitman, 2009). 
Saliva contains several antifungal agents such as lactoferrin, histatin and 
β-defensins. Candidacidal agents like histatins have been demonstrated to kill C. 
albicans in low salt concentrations (Pollock et al., 1984; Jainkittivong et al., 
1998). Histatins have also been shown to inhibit germ tube formation, but their 
activity was not confirmed in assays with whole saliva (Xu et al., 1991). In the 
present study the question is addressed if human saliva is able to induce 
transition to yeast growth in a hyphae growth system. We fractionated human 
whole saliva and parotid saliva and tested each fraction for transition to yeast 
growth in an RPMI based hyphae growth-system. The phosphopeptide 
statherin was identified as the major salivary component inducing yeast 
formation. 
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Materials and Methods   
 
Preparation of saliva 
Whole saliva of 4 healthy individuals, aged between 30 and 50 of which two 
women and two men, was collected without stimulation by expectoration. After 
collection, saliva was homogenized by shaking for 1 minute on a vortex mixer 
and subsequently centrifuged for 5 min at 10,000 x g to remove epithelial cells 
and bacteria. The supernatant was used for further studies. Parotid saliva of the 
same 4 individuals was collected with a Lashley cup by stimulation with 
menthol chewing gum. Before use, both whole and parotid saliva were filter-
sterilized with a 0.45 µm pore filter (Schleicher and Schuell Biosciences, Keene, 
NH, USA). 
 
Strain and culture conditions  
C. albicans 315 (ATCC 10231) was cultured aerobically at 30 °C on Sabouraud 
dextrose agar plates. From the agar plates the yeasts cells were inoculated in 
Sabouraud dextrose broth pH 5.6 and cultured overnight at 30 °C under 
shaking conditions. To induce formation of hyphae, C. albicans was grown 
overnight in RPMI 1640 medium with 25 mM Hepes and L-glutamine 
(Gibco/ Invitrogen, Breda, Netherlands) 1:1 diluted in water in a shaking 
incubator at 37 °C under aerobic conditions with 5% CO2. 
 
Hyphae growth assay for C. albicans 
C. albicans hyphae were inoculated at cell densities of 2×104 cfu ml-1 in 
RPMI1640 medium diluted 1:1 with either saliva or saliva-buffer which 
simulates the ionic composition of saliva (2 mM potassium phosphate, 50 mM 
KCl, 1 mM CaCl2 and 0.1 mM MgCl2, pH 7.2) and incubated for 18 h at 
37 °C in 5% CO2 in 24 or 48 well micro-plates (Greiner Bio One, 
Frickenhausen, Germany). After incubation the cells were microscopically 
examined for their morphology. 
 
 
Fractionation of saliva 
Parotid saliva (2 ml) was fractionated by reverse phase (RP) -HPLC using a C8 
column (10 x 120 mm) (Pharmacia Biotech). Elution was performed with a 
linear gradient of 5–45% acetonitrile containing 0.1% trifluoroacetic acid 
(TFA) for 72 min at a flow rate of 4 ml/min. Eluted proteins were pooled in ten 
fractions. The fractions were lyophilized, reconstituted in 2 ml saliva-buffer and 
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tested for hyphae growth inhibition. The active fraction was lyophilized, 
reconstituted in 2 ml HPLC-grade water, and further fractionated on a Vydac 
C18 column (218 TP, 10 x 250 mm, and 10 µm particles; Grace, Deerfield, IL, 
USA), eluted with a gradient of 10–35% acetonitrile containing 0.1% TFA in 
45 min, at a flow rate of 4 ml min-1. The peak fractions were again lyophilized 
and reconstituted in 2 ml saliva-buffer. 
 
SDS-PAGE  
Electrophoresis was performed on NuPAGE 4-12% BIS/TRIS gels (Invitrogen, 
Carlsbad, CA, USA). Samples were prepared by boiling for 5 min in NuPAGE 
LDS sample buffer (Invitrogen). After electrophoresis gels were stained with 
Coomassie Phastgel Blue R-350 dye (GE healthcare) and destained in 10% 
(v/v) acetic acid. 
 
Immunoblotting  
After electrophoresis proteins were transferred from the gel to nitrocellulose 
membranes by semi-dry blotting in an iBlot gel transfer system (Invitrogen). 
After transfer membranes were blocked by incubation in PBS-Tween 20 with 2 % 
bovine serum albumin. Membranes were incubated with sheep anti-statherin 
antibody, which was a kind gift from dr. Guy Carpenter, King’s college London 
(Proctor et al., 2005), and hereafter with rabbit anti-sheep IgG H&L (AbD 
Serotec) and finally with alkaline phosphatase-conjugated anti-goat 
immunoglobulin (Dako). For visualization blots were incubated with 5-bromo-
4-chloro-3-indolylphosphate (Roche Diagnostics, Mannheim).  
 
Peptide synthesis 
Peptides were synthesized by solid phase peptide synthesis using Fmoc 
chemistry with a MilliGen 9050 peptide synthesizer (Milligen-Biosearch, 
Bedford, MA, USA). Purification by RP-HPLC and confirmation of 
authenticity by mass spectrometry were conducted as described previously 
(Bikker et al., 2002). 
 
Adhesion assay 
Adhesion assays were performed as described previously (Leito et al., 2008) 
according to the method of Bosch et al.(Bosch et al., 2003). After overnight 
culture of C. albicans in Sabouraud dextrose broth, yeast cells were harvested by 
centrifugation (3,000 x g at 22 ºC for 5 min), washed two times in TBST (10 
mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.4) and suspended in TBST-
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Ca (TBST with 2.5 mM CaCl2) to a density of 1·107 cells/ml. The synthetic 
peptides were dissolved in water and coated on Fluotrac 600 microtiterplates 
(Greiner Bio One, Netherlands) by drying o/n at 50 oC. After coating plates 
were washed twice with TBST and once with water. Subsequently, 100 µl of C. 
albicans yeast cell suspension (1×107 cells ml-1) in TBST-Ca was added to each 
well and incubated at 37 ºC for 2 h. After washing bound micro-organisms 
were detected using 100 µl per well of 1 mM SYTO-13 solution in TBS 
(Invitrogen, Eugene, Oregon, USA), a cell permeating and DNA-binding 
fluorescent probe. Plates were incubated in the dark at 37 ºC for 1 hour and 
washed three times with the same buffer. Fluorescence was measured in a 
Fluostar Galaxy microtiterplate fluorescence reader (BMG Laboratories, 
Offenburg, Germany) at 488 nm excitation and 509 nm emission wavelengths. 
 
In-solution binding assay 
10 ml yeast cell or hyphae suspension (containing 1×107 cells) was centrifuged 
(3,000 x g at 22 ºC for 5 min) and resuspended in 120 µl of either parotid saliva 
or peptide solution in saliva-buffer. After incubation at 37 °C for 1 hour cells 
and saliva were separated by centrifugation. The C. albicans pellet was washed 
twice in saliva-buffer. Hereafter, bound components were extracted from the C. 
albicans cells by resuspending the pellet in 120 µl TBS containing 2% SDS and 
incubated at 50 °C for 10 minutes. After centrifugation, the supernatants were 
prepared for electrophoresis. 
 
Ionic charge - - - - - + + + + -
statherin D pS pS E E K F L R R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F
StN6-43 K F L R R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F
StN20-43 P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F
StN6-18 K F L R R I G R F G Y G Y
Table 1. Amino acid sequence of statherin and statherin fragments
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Results 
 
Induction of yeast growth 
First we determined the optimal saliva-buffer / RPMI1640 ratio to use for 
hyphae culture, resulting in a 1:1 dilution of saliva-buffer/RPMI. To investigate 
whether saliva was able to induce yeast growth an overnight culture of C. 
albicans hyphae was used to inoculate RPMI1640 medium 1:1 mixed with 
either saliva-buffer, parotid or whole saliva in tissue culture plates. After 17 
hours of incubation in RPMI medium with whole saliva about 99% of the 
culture consisted of yeast cells and with parotid saliva 95% whereas in RPMI 
medium with saliva-buffer only hyphae were observed (Figure 1). Parotid saliva 
of four other subjects was tested and showed similar effects. 
 
 
Fig. 1 Effect of different types of saliva on hyphae formation. 
C. albicans hyphae were inoculated at a concentration of 1×104 cfu per ml in RPMI medium 
mixed 1:1 with whole saliva, parotid saliva or saliva-buffer. Incubation was performed for 16 
hours at 37 oC and 5% CO2 in tissue culture plates. Samples were analyzed by light microscopy 
at 100 x magnification. Both whole saliva and parotid saliva induce transition to yeast growth. 
 
Parotid saliva Whole saliva
Saliva-buffer
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Fig. 2. Identification of statherin as the factor responsible for induction of yeast growth. 
(a) Two milliliters of parotid saliva was applied on a C8 RP column. Proteins were eluted as 
described in Materials and methods. The numbered peak fractions were collected separately, run 
on 4–12% Bis-Tris gels and stained with Coomassie PhastGel Blue R-350. (b) Immunoblot 
analysis of parotid saliva and parotid saliva fractions from subject 1 and subject 2. S, synthetic 
peptide statherin; H, synthetic peptide histatin 1; P, parotid saliva. Fraction 8 of subject 1 and 
fraction 7 of subject 2 displayed immunoreactivity with anti-statherin. Fractions 3, 4, 5 and 7 
(subject 1) as well as fractions 3, 4 and 6 (subject 2) were negative. (c) HPLC fractions were 
lyophilized and solved in 2 mL of saliva buffer. C. albicans hyphae were inoculated at a 
concentration of 1 x 104 CFU/mL in RPMI medium that was mixed 1:1 with saliva buffer (1), 
parotid saliva (2), HPLC fraction 4 (3) and HPLC fraction 8 (4).Incubation was carried out for 
16 h at 37 °C and 5% CO2 in tissue culture plates. Samples were analyzed by light microscopy 
at 100 x magnification. Of the 10 fractions collected, only fraction 8 induced transition from 
hyphae to yeast. As an example, representative of the inactive fractions, the result obtained with 
fraction 4 is shown. 
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Purification of the hyphae inducing component 
To investigate which components in saliva were responsible for the transition 
from hyphae to yeast growth, parotid saliva of two subjects was fractionated by 
HPLC on a C8 reverse phase column and peak fractions were directly analyzed 
by SDS-PAGE (Figure 2 A). All peak fractions were tested for induction of 
yeast growth. Fraction 8 of subject 1 and fraction 7 of subject 2, which 
migrated at the same elution time, were the only fractions that induced yeast 
growth (Figure 2 C4). SDS-PAGE analysis of these fractions revealed the 
presence of a weakly staining protein band at an apparent molecular mass of 
approximately 6 kDa. Considering the absorbance in the HPLC, this band 
showed weak staining with Coomassie Brilliant Blue. For instance fraction 7 
(subject 1) which on basis of the HPLC profile contained much less protein, 
produced a much more intensely stained band than fraction 8 (subject 1). Based 
on the molecular mass of the band in fraction 8 and 7, respectively, statherin or 
histatin 1, which in parotid saliva are present in substantial concentrations, were 
predicted as possible candidates. Immunoblot analysis of these fractions with 
anti-statherin antibody revealed that the major band in the active fraction was 
statherin (Figure 2 B). Other fractions (e.g. fraction 3, 4, 5, and 7 of subject I), 
which migrated in SDS-PAGE at the same position, but had different retention 
times in HPLC chromatography, were negative (Figure 2 B). The moderate 
Coomassie staining of the statherin bands in fraction 7 and 8 (Figure 2) might 
be due to its high content of proline residues, which weakly bind to Coomassie 
Brilliant Blue. Spiking fraction 8 with synthetic statherin and histatin 1, 
respectively, confirmed that synthetic statherin co-migrated in HPLC with the 
major peak of the active fraction, whereas synthetic histatin 1 eluted at a 
different position (Figure 3 C, E). To establish further the identity of the active 
component, statherin and histatin 1 were synthesized and tested for their effect 
on hyphae growth (Figure 4). This revealed that of these peptides only statherin 
induced transition from hyphae to yeast, confirming again that statherin is the 
active component in parotid saliva.  
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Fig. 3 Identification of the yeast-inducing factor using HPLC chromatography. 
RP-HPLC chromatography on C18 of saliva fraction 8 (Figure 2) and various synthetic 
peptides. Fractions were dissolved in saliva buffer to a final concentration of approximately 50 
µg/ml. A: fraction 8 (individual 1, see Figure 2); B: synthetic statherin; C: fraction 8 spiked 
with 50 µg/ml statherin; D: synthetic histatin 1; E: fraction 8 spiked with 50 µg/ml histatin 1. 
Statherin co-eluted within fraction 8. In contrast, histatin 1 eluted at a different position, both 
in saliva buffer and in fraction 8. Because a different type of chromatography column was used  
(C18 instead of C8), elution times differ from those in figure 2. 
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 Mapping of the yeast growth inducing part of statherin 
Statherin is a 43 residues phosphopeptide with three distinct structural motifs: 
an α-helical structure at the N-terminal domain (Asp1 - Tyr16), a middle 
proline-rich domain (Gly19 -Gln35), and a 310-helical structure at the C-terminal 
Pro36-Phe43 sequence. It contains two phospho-serines at position 2 and 3. 
Together with Asp1, Glu4 and Glu5 this results in a highly negatively charged N-
terminus which may inhibit interaction with the negatively charged C. albicans 
surface. To map the active domain a number of truncated statherin variants 
were synthesized (Table 1) and their effect on yeast formation tested. This 
revealed that the peptide StN6-43 lacking the N-terminal residues exhibited full 
activity (Figure 5 D).  
Synthetic statherin and StN6-43 were tested for yeast transition at 
concentrations of 20, 10, 5, 3.5 µM. Whereas the full statherin at 
concentrations below 20 µM was no longer effective, StN6-43 still exhibited 
activity at a concentration of 3.5 µM (data not shown). The StN6-43 peptide 
was then further divided into two peptides, one from residue 6 to 18 (StN6-18) 
representing a part of the α-helical fragment and the other from residue 20 to 
43 (StN20-43) representing the proline-rich part and 310-helical part of the 
protein. These statherin fragments were synthesized and tested for yeast growth 
induction (Table 1). These two peptides did not stimulate the transition to 
yeast growth suggesting residues in both fragments of statherin are critical for 
activity (Figure 5). 
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Fig. 4. Yeast growth induction by synthetic statherin and histatin 1.  
C. albicans hyphae were inoculated at a concentration of 1×104 cfu per ml in RPMI medium 
mixed 1:1 with saliva-buffer (A), parotid saliva (B), 100 µM synthetic statherin (C) or 100 µM 
synthetic histatin 1 (D). Incubation was performed for 16 hours at 37 oC and 5% CO2 in tissue 
culture plates. Samples were analyzed by light microscopy at 100 x magnification. Synthetic 
statherin induces transition from hyphae to yeast whereas histatin 1 did not. 
 
C. albicans - peptide interaction 
StN6-43 showed a higher yeast inducing activity than the parent statherin 
peptide. To test if this difference was related with the capacity of a given 
peptide to bind to C. albicans  we examined their binding to C. albicans in an 
adhesion assay and an in-solution binding assay. For comparison histatin 1 was 
included.   
For the adhesion assay microtiterplates were coated with peptides followed by 
incubation with a C. albicans suspension. Since hyphae exhibited high 
background adhesion to uncoated microtiterplates they could not be tested in 
the adhesion assay. The adhesion assay conducted with yeast revealed that 
StN6-43 supported adhesion of C. albicans better than the whole statherin 
molecule. Histatin 1 did not support any adhesion (Figure 6). In addition, 
binding of these peptides to C. albicans (yeast and hyphae) was tested in 
solution. In this assay, cells were incubated with synthetic peptides in solution. 
A B
C D
  Hyphae to yeast transition of C. albicans by statherin  
75 
 
After incubation, cells were centrifuged, washed and cell-bound components 
were extracted. The supernatants and the cell extracts were analyzed by SDS 
PAGE (Figure 7).  
These experiments showed that also the in-solution-binding assay StN6-43 
bound better than the whole statherin molecule, especially to the yeast form of 
C. albicans (Figure 7). SDS PAGE analysis of histatin 1 revealed a shift to a 
lower molecular mass position, suggesting degradation of the peptide upon 
incubation with the yeast form.  
 
 
 
Fig. 5. Yeast growth induction by statherin and statherin fragments 
C. albicans hyphae were inoculated at a concentration of 1×104 cfu per ml in RPMI medium 
mixed 1:1 with saliva-buffer as a control (A) , St6-18 (B), St20-43 (C), St6-43 (D) and full 
length statherin (E). All peptides where tested at a concentration of 20 µM. Incubation was 
done for 16 hours at 37 oC and 5% CO2 in tissue culture plates. Samples were analyzed by light 
microscopy at 100 x magnification. St6-43 showed higher yeast growth inducing effect than 
statherin. The shorter peptides did not induce transition to yeast. 
B
C
E
D
A
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Fig. 6. Adhesion of C. albicans yeasts to statherin and St6-43 
C. albicans yeast suspension were incubated in micro-plates coated with peptides for 2 h at 37 
ºC. Unbound yeasts were washed away. Bound C. albicans were fluorescently labeled and the 
fluorescence signal was measured. C. albicans showed better adhesion to St6-43 than to the 
whole statherin. Histatin 1 did not support adhesio
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Fig. 7. In-solution-binding assay of synthetic peptides with C. albicans  
C. albicans hyphae and yeasts were incubated in solutions of synthetic statherin, St6-43, and 
histatin 1 (final concentrations approximately 20 µM) for 1 h at 37 °C. After centrifugation the 
supernatant containing the residual unbound peptide was collected. From the pellet the cell 
bound components were extracted with 2% SDS. The supernatants and extracts were analyzed 
by SDS-PAGE. As a control for compounds originating from C. albicans, C. albicans was 
incubated in saliva buffer and analyzed in the same way.  
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Discussion 
This study demonstrates that whole saliva and parotid saliva promote the 
transition of C. albicans to the yeast form in a hyphae growth system. The 
salivary component responsible for this transition was identified as statherin. In 
an earlier report synthetic histatins inhibited germ tube formation, especially 
histatin 3 (Xu et al., 1991). Another paper reported that human saliva inhibits 
germ tube formation but could not confirm the role of histatins possibly due to 
complexation of histatins with other salivary proteins (Xu et al., 1991; Santarpia 
et al., 1992). In this paper histatin 1 was also tested for inducing transition to 
yeast growth, but no effect was found in our system.  
Statherin is a 43-residue acidic salivary phosphopeptide. Its gene is 
encoded on chromosome 4 and shows homology with the HIS1 gene for 
histatins (Sabatini et al., 1993). Statherin is secreted by the parotid and 
submandibular/sublingual salivary glands. The concentration of statherin in 
saliva is in the range of 16–160 µg/ml (Hay et al., 1984). The concentration 
that we used in the hyphae inhibition assay (100 µg/ml) is within this range and 
thus is physiologically relevant. Since the hyphal form of C. albicans is 
considered to be more infectious than the yeast form inhibition of hyphae 
formation may play a role in vivo (Lo et al., 1997; Saville et al., 2006).  
Statherin is among the first salivary proteins that bind to the enamel 
surface and is considered to be of prime importance in protecting the teeth 
(Hannig et al., 2004). Coated onto the dental surface statherin binds a variety 
of micro-organisms, including C. albicans (Gibbons and Hay, 1988; Gibbons et 
al., 1988; Johansson et al., 2000). This was confirmed in our binding assays 
where we found a good adhesion of yeast cells to statherin-coated microplates. 
Previous research has shown aggregation of C. albicans by 2 mg/ml statherin in 
solution (Johansson et al., 2000), which is 20-fold higher than the 
concentrations we used (100 µg/ml) in our in solution binding assay.  
Statherin shows a high electrical charge asymmetry. A significant 
number of negatively charged residues is localized in the N-terminal region 
(DpSpSEE). This is followed by a short positively charged region, whereas the 
C-terminal region contains mainly uncharged residues. The first five negatively 
charged amino acids are responsible for the coating of statherin on 
hydroxyapatite (Raj et al., 1992). Remarkably, when these five amino acid were 
absent, as in StN6-43, the yeast inducing effect was enhanced. The decreased 
repelling forces between the negatively charged amino acids and the negatively 
charged cell surface of C. albicans could explain this. This was confirmed by the 
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observation that StN6-43 compared to statherin gave a better adhesion of C. 
albicans and clearly showed binding in solution to both yeast cells and hyphae. 
StN6-43 on its turn was further divided into a proline-rich part StN20-43 and 
StN6-18 that has a strong positive charge due to one lysine and three arginine 
residues. Both fragments did not stimulate transition to yeast growth as 
effectively as the StN6-43 peptide suggesting that residues on both fragments 
are required for transition to yeast growth. This result is in line with the result 
of Niemi and Johansson who only found binding of C. albicans to intact 
statherin and not to StN1-32 or StN33-43 (Niemi and Johansson, 2004).  
Since the hyphal form of C. albicans is considered to be more virulent 
than the yeast form inhibition of hyphal growth of C. albicans by saliva may be 
one of the effects by which saliva prevents the development of candidiasis in 
individuals carrying of C. albicans in the oral cavity. For people suffering from 
dry mouth, immuno-compromised people and people that are sensitive for 
Candida outgrowth in general, statherin based peptides such as StN6-43 might 
be an interesting additive in antifungal applications. 
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Abstract 
Candida albicans, a major fungal pathogen in humans, may undergo a reversible 
morphological transition from the yeast form to the more virulent hyphae form. 
Previously we demonstrated that statherin, a 43 residue peptide implicated in 
the mineral homeostasis of saliva, induces hyphae-to-yeast transition (Chapter 
4). The aim of this study was to map the minimal domain of statherin that is 
responsible for this activity. For this purpose, truncated statherin peptides were 
synthesized and added to C. albicans hyphae cultures. Hyphae growth was 
scored microscopically. Cultures without statherin peptides showed only hyphae 
growth. Hyphae-to-yeast inducing activity enhanced by removal of the first nine 
N-terminal amino acids of statherin (StN10-43). By removal of another four 
residues (StN14-43) activity disappeared. By C-terminal truncation of StN10-
43 activity decreased. StN10-29 was still active, but StN10-19 was not. Most 
truncated variants that induced hyphae-to-yeast transition also caused 
detachment of adhered hyphae from the culture plates.  
These results show that fragments of statherin are able to induce hyphae-to-
yeast transition in C. albicans. 
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Introduction 
Candida albicans is the most widespread fungal pathogen in humans and can 
cause life-threatening systemic infections. C. albicans is a common constituent 
of the microflora of the gastro-intestinal tract. At these sites disturbance of the 
ecological balance in the mucosal flora may cause opportunistic infections with 
C. albicans, such as vaginitis or thrush. Known factors that can cause this 
disturbance are use of antibiotics and compromised immunity by for instance, 
radio-therapy, AIDS or surgery (Soll, 2002). 
An important feature of C. albicans, relevant for its pathogenesis, is its 
ability to switch between different morphological forms. C. albicans can grow in 
a unicellular yeast form, known as blastospores or blastoconidia, or in 
filamentous structures known as pseudohyphae and true hyphae (Berman, 
2006). Under influence of a number of environmental signals, such as osmotic 
shock, alterations of temperature, pH and nutrients, yeasts can switch to the 
filamentous form (Buffo et al., 1984). While yeasts are important for 
dissemination within the host, hyphae are essential for outgrowth and biofilm 
formation (Lo et al., 1997; Bastidas and Heitman, 2009). Compared to the 
yeast form hyphae show stronger binding to epithelial cells and can penetrate 
human tissue. Therefore, the hyphae form is considered to be the most virulent 
form of C. albicans (Zheng et al., 2004; Bastidas and Heitman, 2009). 
Saliva contains several antifungal agents that are able to kill C. albicans, 
such as histatins, LL-37 and β-defensins, or inhibit its growth, such as 
lactoferrin (Pollock et al., 1984; Jainkittivong et al., 1998; van der Kraan et al., 
2004; Matejuk et al., 2010). In a previous study we revealed an alternative 
mechanism by which saliva controls C. albicans infection. In the presence of 
salivary statherin C. albicans grows in the yeast form under circumstances that 
normally induce hyphae growth. Statherin is a 43 residues calcium-binding 
phosphopeptide which, as constituent of the tooth pellicle, plays a role in the 
mineral homeostasis of saliva by keeping saliva supersaturated with respect to 
calcium phosphate.  
In the present study we have mapped the minimal active domain of 
statherin that is responsible for the transition of hyphae-to-yeasts of C. albicans. 
For this purpose, fragments of the statherin molecule were evaluated for their 
ability to induce hyphae-to-yeast transition. A peptide representing residues 10-
43 of statherin induced the strongest hyphae-to-yeast transition. A peptide 
representing the residues 6-18 was the shortest fragment that still induced 
hyphae-to-yeast transition.  
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Materials and Methods 
 
Peptide synthesis 
Peptides were synthesized by solid phase peptide synthesis using Fmoc 
chemistry with a MilliGen 9050 peptide synthesizer (Milligen-Biosearch, 
Bedford, MA, USA). Purification by reversed phase-HPLC and confirmation of 
authenticity by mass spectrometry were conducted as described previously 
(Bikker et al., 2002). Truncated statherin peptides were denoted StN with the 
corresponding residues in the whole protein, for example StN10-43 consists of 
the residues 10 to 43 of the full length statherin.  
 
Strain and yeast cell culture conditions  
C. albicans 315 (ATCC 10231) was cultured aerobically at 30 °C on Sabouraud 
dextrose agar plates (Oxoid, Hants, UK). From the agar plates the yeasts cells 
were inoculated in Sabouraud dextrose broth pH 5.6 and cultured aerobically 
overnight at 30 °C under shaking conditions. This culture was diluted 1:50 in 
fresh medium and grown for 6 h until early stationary phase.  
 
Hyphae-to-yeast induction 
C. albicans yeast cells were inoculated at densities of 50 cfu ml-1 in RPMI 1640 
medium with 25 mM Hepes and L-glutamine (Gibco/Invitrogen, Breda, 
Netherlands) diluted 1:1 with H2O. Cultures were incubated for 18 h at 37 °C 
under aerobic conditions with 5% CO2 in 48 wells micro-plates (Greiner Bio-
One, Frickenhausen, Germany). This condition induced the transition of yeasts 
to the hyphal morphology. After culturing C. albicans was present as clusters of 
hyphae attached to the bottom of the wells of the culture plate. Then medium 
was removed and 500 µl of the same medium containing 20 µM of peptide was 
added. The plates were incubated for 18 h at 37 °C and 5% CO2. After 
incubation the medium was mixed with a pipet and transferred to a Neubauer 
counting chamber to determine the number of yeast cells that had been 
generated upon incubation with peptide. The yeast cells within 16 squares, 
corresponding to a volume of 100 nl, were counted. To determine the 
detaching effect of the peptides the fluid was removed and the residual number 
of hyphae clusters attached to the bottom of the wells was determined.  
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Analysis of peptide-binding to C. albicans .  
Early stationary phase C. albicans culture was centrifuged and resuspended in 
PBS. After a second centrifugation step yeast cells were suspended in PBS to a 
density of 1×107 cells/ml. 360 µl cell suspension was supplemented with 40 µl 
of peptide solution in a 48 well culture plate (Greiner) to a final peptide 
concentration of 20 µM. Plates were incubated for 1 h at 37 °C. To control for 
non-specific adsorption of peptides to the microplate wells, parallel incubations 
were conducted with peptides alone. At the start and after 1 h a 50 µl aliquot 
was taken and centrifuged (10,000 x g, 5 min) for determination of the peptide 
concentration. The amount of peptide before and after incubation was 
determined by capillary zone electrophoresis (CZE) on a Bio-Focus 2000 
capillary electrophoresis system (Bio-Rad, Hercules, CA) as described by 
Ruissen et al. (Ruissen et al., 2002).  
Binding of peptides to the hyphae form was determined essentially the same 
way. C. albicans hyphae were grown as described above for hyphae-to-yeast 
induction in 48 well culture plates. After 18 h medium was carefully removed 
by aspiration, and hyphae, attached to the bottom of the culture plate, were 
washed twice with PBS. Then 400 µl of a 20 µM peptide solution in PBS was 
added and incubation was performed for 1 h at 37 °C. At the start and after 1 
hour aliquots were taken and centrifuged (10,000 x g, 5 min). Peptide 
concentrations in the supernatant were analyzed by CZE. 
 
Table 1. Amino acid sequence and functional activities of the peptides used in this study
Ionic charge – – – – – + + + + –
1Yeast
Growth
Hyphae 
detachment
2Yeast
Binding
Statherin D pS pS E E K F L R R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F + + ++ +
StN6-43 K F L R R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F + + ++ +
StN10-43 R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F + + ++ +
StN14-43 F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F – –
StN20-43 P Y Q P V P E Q P L Y P Q P Y Q P Q Y Q Q Y T F – – –
StN10-37 R I G R F G Y G Y G P Y Q P V P E Q P L Y P Q P Y Q P Q + ++
StN10-29 R I G R F G Y G Y G P Y Q P V P E Q P L + ++
StN10-19/37-43 R I G R F G Y G Y G - - - - - - - - - - - - - - - - - Q Y Q Q Y T F + +
StN10-19 R I G R F G Y G Y G – +
StN6-18 K F L R R I G R F G Y G Y + – +
HIS 1 D S H E K R H H G Y R R K F H E K H H S H R E F P F Y G D Y G S N Y L Y D N – + –
CYS 1-13 S S S K E E N R J J P G G – – –
1 ++: strong hyphae-to-yeast induction; +: moderate hyphae-to-yeast induction; -: no hyphae-to-yeast induction
2 ++: strong hyphae detachment; +: moderate hyphae detachment; -: no hyphae detachment
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Results 
 
Determination of the minimal active domain of statherin 
We synthesized a series of statherin fragments, truncated at the N- and C-
termini (Table 1). These peptides were evaluated for their potential to induce 
transition to yeast growth in a hyphae growth system in a concentration of 20 
µM. As negative control the solvent alone was used (1:1 diluted RPMI), 20 µM 
histatin 1 (HIS1, 38 residues) (Leito et al., 2009) and CYS1-13, a peptide 
representing the N-terminal 13 residues of cystatin S. 
Fig. 1. Effect of statherin peptide StN6-43 on hyphae-to-yeast transition of C. albicans. C. 
albicans hyphae were cultured for 17 h at 37 ºC with 5% CO2 in medium with (A) or without 
(B) 20 µM StN6-43.  
   
Figure 1A shows a microscopic picture obtained after incubation of hyphae with 
peptide StN6-43 revealing that compared to the control the number of yeast 
cells was increased. In the control only hyphae clusters were visible (Fig. 1B).  
 By deletion of the N-terminal amino acids of statherin, as in StN6-43 
and StN10-43, hyphae-to-yeast inducing activity increased, with peptide 
StN10-43 showing the highest activity (Fig. 2). By further deletion of N-
terminal amino acids, as in peptides StN14-43 and StN20-43, activity 
disappeared (Fig. 2). C-terminal truncation of StN10-43 resulted in a decrease 
of activity in StN10-37 and StN10-29. StN10-19 showed no activity, but N-
terminal elongation, as in peptide StN6-18, restored its activity partially. Also 
elongation of this peptide with residues 37-43 (StN10-19/37-43) restored its 
activity.  
 
A B
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Fig. 2. Hyphae-to-yeast-inducing activities of statherin
C. albicans hyphae were cultured for 20 h under hyphae
Materials and Methods in the presence of 20 µ
Neubauer counting chamber. Results represent mean and SD (error bars) of three samples
Control: hyphae culture without peptides. 
 
Detachment of hyphae clusters 
We observed that peptides inducing the hyphae
detachment of hyphae clusters from the bottom of the wells of the culture plates. 
Therefore, we counted the number of attached hyphae clusters before and after 
incubation with peptides (Fig. 3). Hyphae
detachment correlated (p < 0.05), but were not directly linked. E.g. StN6
induced hyphae-to-yeast transition, but no hyphae detac
other hand StN10-19 and histatin 1, while not inducing hyphae
transition, did cause detachment of hyphae. 
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-derived peptides. 
-inducing conditions as described in 
M peptides. Yeast cells were counted using a 
. 
-to-yeast transition caused 
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hment, whereas on the 
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Fig. 3. Effect of statherin-derived peptides on the detachment of hyphae 
C. albicans hyphae were cultured for 20 h under hyphae
Materials and Methods in the presence of 20 µ
of hyphae clusters that remained attached to the culture plate wells was counted. The 
shows the tested peptides and the Y-axis shows the number of attached hyphae clusters per well. 
Results represent mean and SD (error bars) of three samples.
 
Binding of peptides to C. albicans hyphae and yeasts 
To investigate whether there are differences in binding properties for peptides 
between hyphae and yeasts several peptides were evaluated for binding to both 
forms of C. albicans (Fig. 4). StN6-43 
cell growth and hyphae detachment, bound to both yeast cells and hyphae. 
StN6-18, which did not induce detachment of hyphae, bound to both yeasts 
and hyphae. Cys1-13 did not bind to either hyphae or yeasts. These results 
suggest that there are no essential differences for bin
either hyphae or yeasts.  
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M peptide. After washing with PBS the number 
X-axis 
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ding of the peptides to 
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Fig. 4. Binding of peptides to C. albicans yeasts (A) and hyphae (B)  
(A) Peptide solutions (20 µM) were incubated in 48 wells plates with (A1) or without yeast cells 
(A0). After 1 h samples were taken and peptide concentrations were determined by CZE with 
imidazole as an internal standard. The horizontal axis shows the decrease in peptide 
concentration compared to the control (A1 –A0).  
(B) 48-wells culture plates covered with hyphae were incubated with 400 µl 20 µM peptide 
solution at 37 °C (B1). Peptide solutions in 48 wells plates without hyphae served as a control 
(B0). Samples were taken after 1 h. The peptide concentration was determined by CZE with 
imidazole as an internal standard. The horizontal axis shows the decrease in peptide 
concentration compared to the control solution (B1 – B0).  
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Discussion 
In Chapter 4 we showed that salivary statherin is able to induce the transition of 
hyphae to yeast cells under hyphae growth conditions (Leito et al., 2009). In the 
present study we mapped the active domain within statherin responsible for this 
effect. For this purpose statherin was truncated systematically from the N-
terminal and the C-terminal side and synthetic fragments were tested for 
hyphae-to-yeast induction.  
When N-terminal residues were deleted hyphae-to-yeast inducing 
activity increased with StN10-43 being the most active peptide. Further 
deletion of 4 N-terminal residues, in StN14-43, abolished activity. When 
StN10-43 was truncated from the C-terminal side hyphae-to-yeast inducing 
activity gradually decreased and disappeared in StN10-19. Elongation of this 
peptide, either N-terminally (StN6-18) or C-terminally (StN10-29 or StN10-
19/37-43) restored somewhat hyphae inhibiting activity, suggesting a minimal 
size was required for hyphae-to-yeast induction.  
Hyphae-to-yeast inducing peptides caused the detachment of firmly 
attached hyphae clusters from the polystyrene surface. However, the results for 
StN6-18, which induced yeast growth but did not cause hyphae to detach, and 
StN10-19 and histatin, who did the opposite, suggest two independent 
mechanisms.  
 In Chapter 4 we found that StN6-43 binds stronger to C. albicans than 
the whole statherin molecule, possibly because the absence of the negatively 
charged N-terminus results in less repulsion at the negatively charged C. 
albicans cell surface. Compared to StN6-43, StN10-43 shows the highest yeast 
growth inducing activity and binds equally well to C. albicans hyphae and yeasts 
suggesting that further truncation might be possible.  
During granule maturation in vivo in parotid and submandibular 
glands, statherin can be cleaved by endo-peptidases which may give rise to the 
secretion of peptides StN14-43 and StN10-43 into the oral cavity. The latter 
peptide shows high hyphae-to-yeast-inducing activity (Messana et al., 2008). 
Since several statherin peptides cause transition to yeast it might be 
interesting to see whether the virulence is also influenced by these peptides. In a 
study done by Carlisle et al. (2009) C. albicans filament formation was linked to 
its virulence in a mouse model for systemic C. albicans infection (Banerjee et al., 
2008; Carlisle et al., 2009). In this context it might be interesting to study the 
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effect on the expression of genes in C. albicans that induce hyphae formation, 
such as UME6 (Carlisle et al., 2009).  
In conclusion, we show here that truncated statherin variants show 
higher yeast growth induction than the full statherin molecule with the highest 
activity in StN10-43. Furthermore, we demonstrate that peptides that induce 
hyphae-to-yeast transition generally also cause hyphae to detach from the 
microplate wells.  
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Abstract 
Salivary agglutinin (SAG), also known as gp-340 and Deleted in Malignant 
Brain Tumours 1, is a glycoprotein that is present in tears, lung fluid and 
mucosal surfaces along the gastrointestinal tract. It is encoded by the Deleted in 
Malignant Brain Tumours 1 gene, a member of the Scavenger Receptor Cysteine 
Rich group B protein superfamily. SAG aggregates bacteria thus promoting 
their clearance from the oral cavity and activates the complement system. 
Complement proteins may enter the oral cavity in case of serum leakage, which 
occurs after mucosal damage. The purpose of this study was to investigate the 
mode of complement activation. We showed a dose-dependent C4 deposition 
on SAG-coated microplates showing that either the classical or lectin pathway 
of complement was activated. Antibodies against mannose binding lectin 
inhibited C4 deposition and SAG induced no C4 deposition in MBL deficient 
sera showing SAG activated complement through the mannose binding lectin 
(MBL) pathway. Periodate treatment of SAG abolished MBL pathway 
activation consistent with an involvement of SAG glycans in complement 
activation. This provides the first evidence for a role of SAG in complement 
activation through the MBL pathway and suggests a potential role of SAG as a 
complement activating factor at the mucosal epithelia. 
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Introduction 
Salivary agglutinin (SAG) is a glycosylated protein known for its ability to bind 
and aggregate a wide spectrum of micro-organisms including bacteria, fungi and 
viruses. SAG is encoded by the Deleted in Malignant Brain Tumours 1 (DMBT1) 
gene which is expressed by epithelial cells of the alimentary and respiratory tract 
and is secreted by salivary and lacrimal glands (Holmskov et al., 1997; 
Mollenhauer et al., 2001; Ligtenberg et al., 2007). SAG belongs to the 
scavenger receptor cysteine-rich superfamily, a group of proteins that are 
primarily involved in innate defence processes (Kang and Reid, 2003; 
Ligtenberg et al., 2007).  
In addition to its interaction with micro-organisms, SAG stimulates alveolar 
macrophage migration and suppresses neutrophil oxidative burst, which are 
different ways to protect against micro-organisms and/or excessive tissue 
damage (Holmskov et al., 1999; White et al., 2005). These interactions suggest 
an important role for SAG as an innate immune factor. 
The complement system is an important part of the humoral innate immune 
system (Carroll, 2008) consisting of more than 30 proteins in plasma and on 
cell membranes. The main effector functions of complement activation are 
opsonisation to facilitate phagocytosis of viral, bacterial and fungal pathogens, 
attraction and activation of phagocytes to sites of infection, and removal of 
immune complexes and apoptotic cells. Activation of the complement system 
can occur via three pathways, which are initiated via separate mechanisms and 
eventually converge in a common terminal pathway. The classical pathway is 
initiated by binding of its recognition molecule C1q to IgG- or IgM containing 
immune complexes or other repetitive structures such as the acute phase protein 
CRP. Subsequently, the associated serine proteases cleave and thereby activate 
C2 and C4 molecules. The lectin pathway essentially uses the same molecules as 
the classical pathway e.g. C4 and C2, except that its recognition molecules are 
mannose binding lectin MBL or ficolins that bind to a wide array of 
carbohydrate structures on pathogenic surfaces and are associated with the 
serine proteases MASP-1, MASP-2, MASP-3 and a truncated form of MASP-2 
called Map-19. Finally, activating structures of the alternative pathway are 
present on the cell walls of bacteria, viruses and yeasts, whereas IgA-containing 
immune complexes can also activate the alternative pathway.  
Although separated by an epithelial layer, contact between saliva and blood 
plasma is quite common in the oral cavity; for instance in periodontal diseases 
and after mechanical damage such as surgery or tooth brushing. Under these 
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circumstances blood or plasma leaks into the oral cavity, which results in 
mixture with saliva (Negut et al., 2007). Both saliva and blood are carriers of 
antimicrobial factors such as SAG and complement respectively and it has been 
suggested that upon mixing with saliva, the complement system may contribute 
to host defence mechanisms within the oral cavity (Boackle, 1991). Early 
research by Boackle et. al. (1993) demonstrated the potential of human SAG to 
bind to C1q and to activate C1. 
The aim of the present study was to investigate the activation of complement by 
SAG in detail. We observed that in vitro SAG activates the complement system 
primarily via the MBL mediated lectin pathway and that fucose on SAG is a 
critical determinant of MBL binding and complement activation. 
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Materials and methods 
 
Serum samples 
Serum was collected from healthy volunteers. After drawing blood, it was left to 
coagulate for 1 hour at room temperature (RT) after which, the blood clot was 
removed from the serum. Serum was stored at -80˚C until testing. 
 
Antibodies  
Monoclonal anti-C4-10 against C4 and CLB-MBL/1 against MBL were 
described previously ((Wolbink et al., 1993; Bultink et al., 2006). Anti-MBL/1 
inhibits binding of MBL to its substrates. Monoclonal anti-C1q-85, which 
interferes in the interaction of C1q with its ligands and therefore inhibits 
classical pathway activation, has 
been described before  (Hoekzema et al., 1988; McGrath et al., 2006). 
Monoclonal antibody 213-06 was obtained from the antibodyshop (Gentofte, 
Denmark). Biotinylated Ulex europaeus agglutinin-1 (UEA-1), specific for 
terminal fucose, was from Pierce (Rockford Il, USA). Digoxigenin labeled 
Datura stramonium agglutinin (DSA), specific for terminal N-
acetylglucosamine, was obtained from Roche 
(Roche Diagnostics GmbH, Mannheim, Germany). Galanthus nivalis 
agglutinin (GNA), specific for terminal mannose, was obtained from Roche. 
Aggregated human IgG (AHG) was prepared by incubating purified human 
IgG at a concentration of 20 mg/ml for 20 min at 63 °C. 
 
Collection of crude SAG and purification of SAG 
SAG was purified by affinity adsorption of parotid saliva to S. mutans as 
described previously (Ligtenberg et al., 2000). S. mutans UA159 was cultured in 
100 ml Todd Hewitt Broth by overnight (o/n) incubation at 37 °C. The 
bacteria were pelleted by centrifugation at 15,000 x g at RT, washed 2 times in 
phosphate buffered saline (PBS), pH 7.4 and then resuspended in 5 ml PBS. 35 
ml of parotid saliva was collected with a Lashley cup under stimulation with 
menthol chewing gum and centrifuged for 2 minutes to get rid of debris. The 
bacteria suspension was then mixed with parotid saliva and incubated by 
shaking for 1 hour at 37 °C. The bacteria were then pelleted by centrifugation 
(15,000 x g, RT) and washed 2 times with PBS containing 1 mM CaCl2. 
Bacteria were resuspended in 4 ml PBS containing 10 mM EDTA to elute the 
bound SAG and incubated for 20 minutes by shaking at RT. Bacteria were then 
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pelleted and discarded. The supernatant was then again centrifuged for 10 min 
at 20,000 x g at RT after which the pellet was discarded and the supernatant 
was transferred to a separate tube. The purity of the SAG preparation was tested 
by means of SDS-PAGE and Coomassie staining (Fig. 1) showing one major 
band at approximately 340 kD. SAG concentration was determined by Bio-Rad 
protein microassay procedure for microtiterplates and ranged from 70 to 80 
µg/ml. 
 
Periodic acid treatment  
For periodic acid oxidation of SAG carbohydrates, SAG was first diluted in 
coating buffer (0.1 M carbonate buffer, pH 9.6) and immobilized on 96-wells 
plates (Nunc MaxiSorp™, Roskilde, Denmark) by o/n incubation at 4 °C. The 
SAG coated plates were then incubated for 1 hour in 0.1 M in acetic acid (pH 
4.2) containing 20 mM NaIO4. The plates were then washed 3 times with H2O 
followed by a 1 hour reduction with 50 mM NaBH4 in PBS. The plates were 
washed then 3 times with H2O and used for testing.  
 
Functional MBL concentration 
Functional MBL concentration was determined in a solid phase ELISA with 
mannan coated onto the solid phase and detection with biotinylated monoclonal 
antibody anti-MBL/1. Briefly, microtiterplates (Nunc Maxisorp) were coated o/n 
at RT with mannan (Sigma-Aldrich, St Louis, MO, USA; 50 µg/ml in 0.1M 
carbonate buffer, pH 9.6). In between incubations microtiterplates were washed 
five times with H2O. Sera were diluted in 20 mM Tris (pH 7.4) supplemented 
with 150 mM NaCl, 10 mM CaCl2, 0.02% Tween and 0.2% gelatin (TTG/Ca) 
and incubated for 1 hour at RT. Bound MBL was detected by biotinylated anti-
MBL/1 (2 µg/ml in TTG/Ca) for 1 hour at RT. Functional MBL concentration 
was calculated on a titration curve of a serum pool of healthy donors. MBL 
concentration below 500 ng/ml was considered MBL-deficient.  
 
C4 deposition on SAG 
Microtiterplates (Nunc MaxiSorp) were coated o/n at 4 °C with 10 µg/ml 
purified SAG (either untreated or treated with periodic acid) in 0.1M carbonate 
buffer, pH 9.6. For control experiments microtiterplates were coated o/n at RT 
with 20 µg/ml  AHG in PBS or 50 µg/ml mannan in 0.1M carbonate buffer. All 
incubations were performed in a final volume of 100 µl. Serum samples were 
diluted 1:10, followed by threefold dilutions in Veronal buffered saline, pH 7.4 
supplemented with 10 mM CaCl2, 2 mM MgCl2 and 0.02% Tween-20 and 
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incubated for 1 hour at RT. To specifically inhibit either the classical or the lectin 
pathway of complement, all serum dilutions were incubated in the presence of 
blocking monoclonal antibodies against C1q (anti-C1q-85, 50 µg/ml) or MBL 
(anti-MBL/1, 10 µg/ml). Subsequently, plates were washed five times with 
PBS/0.02% Tween-20. To detect C4 deposition, plates were incubated for 1 
hour at RT with biotinylated anti-C4-10 (0.25 µg/ml), diluted in high 
performance ELISA buffer (HPE; Business Unit reagents, Sanquin, Amsterdam, 
the Netherlands). After five washes with PBS/0.02% Tween-20, plates were 
incubated with streptavidin-peroxidase (Amersham/Pharmacia, Uppsala, Sweden) 
(1:1000 in HPE) for 30 minutes at RT. After five washes with PBS/0.02% 
Tween-20, the ELISA was developed with 100 µg/ml tetramethylbenzidine in 
0.11 M sodium acetate (pH 5.5) containing 0.003% v/v H2O2. Substrate 
conversion was stopped by addition of 100 µl H2SO4. Absorbance was measured 
at 450 nm with a Titertek multiscan. 
 
MBL binding to SAG 
MBL binding to SAG (either untreated or treated with periodic acid) was 
detected in an ELISA similar to the C4 deposition ELISA with some 
modifications. In short, plates were coated with SAG as described above. Serum 
samples were diluted 1:3 in TTG/Ca followed by threefold dilutions and 
incubated at RT. MBL binding was detected with biotinylated anti-MBL/1 (2 
µg/ml in TTG/Ca). ELISA was developed as described above. 
 
Detection of carbohydrates on SAG 
SAG was coated in twofold serial dilutions (0-20 µg/ml in 0.1M carbonate 
buffer, pH 9.6) o/n at 4 °C in 96 wells microtiterplates (Nunc MaxiSorp). After 
washing, detection of carbohydrates was performed using digoxigenin (DIG)-
labeled lectins GNA and DSA for the detection of mannose and N-acetyl-D-
glucosamine (GlcNAc) respectively, and biotinylated UEA-1 lectin for the 
detection of fucose. As a control for coating of SAG we used monoclonal 
antibody HYB 213-06 that recognizes part of the protein core SAG (Bikker et 
al., 2002). Lectins and antibody were diluted 1:2000 (final concentration 0.5 
µg/ml) in Tris Buffered Saline (TBS) at pH 7.5 containing 1 mM MgCl2, 1 
mM MnCl2, 1 mM CaCl2 supplemented with 2% BSA and 0.1% Tween-20 
and incubated for 1 hour. The plates were then washed 3 times with TBS/0.01% 
Tween-20 and rinsed with H2O. After washing, DIG-labeled lectins were 
incubated with 75 mU/ml peroxidase-conjugated anti-DIG Fab-fragments 
(Boehringer Mannheim, Roche, Netherlands). Biotinylated UEA-1 was 
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incubated with streptavidin-peroxidase (Amersham/Pharmacia). HYB 213-06 
was incubated with 0.65 µg/ml peroxidase-conjugated rabbit-anti mouse 
antibody (Dako, Belgium). All incubations were done for 1 hour in TBS 
containing 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2 supplemented with 2% 
BSA and 0.1% Tween-20 and then were washed 3 times with TBS/0.01% 
Tween-20 and rinsed with H2O. Enzymatic-staining was done using 
SIGMAFAST TM OPD tablet-kit (Sigma-Aldrich, Netherlands). The reaction 
was stopped by adding 50 µl 0.05 M sulfuric acid. Microtiterplates were read at 
450nm using a MR7000 ELISA-reader (Dynatech, VA, USA). 
 
  
 
Fig 1. SDS-PAGE analysis of purified SAG. SAG was purified by affinity adsorption of 
parotid saliva to S. mutans. Purity of SAG was shown by SDS-PAGE and Coomassie staining. 
Lane (1). Parotid saliva, Lane (2) SAG extract. The location of SAG is indicated by the 
arrowhead. 
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Results 
 
Complement activation by SAG  
Purified SAG (Fig. 1) was immobilized on microtiterplates in twofold serial 
dilutions (0 - 20 µg/ml) and tested for complement activation by detection of 
C4 deposition as described (Fig. 2). Serum of three healthy subjects (diluted 1: 
50) clearly demonstrated C4 deposition on immobilized SAG indicating that 
SAG is able to activate the complement system. C4 deposition was dose 
dependent and was completely absent in the presence of 10 mM EDTA, ruling 
out non-specific direct binding of C4 from the serum to the coat.  
 
 
 
Fig 2. Immobilized SAG induces C4 deposition. Serum was incubated (1:50 dilution) on 
serially diluted immobilized SAG in VB++ or in VB/10 mM EDTA. Results represent mean and 
SEM (error bars) of 3 MBL-sufficient donors.  
 
C4 activation by SAG dependent on MBL 
C4 activation may be the result of either the classical or the lectin complement 
pathway. To identify which complement pathway is activated by SAG, either 
the classical or the lectin pathway was inhibited by incubation with blocking 
monoclonal  antibodies against C1q and MBL (Fig. 3). Incubation with anti-
C1q-85 and anti-MBL/1 completely blocked C4 deposition on AHG and 
mannan, respectively (Supplementary figure 1). 
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Fig 3. C4 deposition on immobilized SAG is primarily mediated by MBL 
Serum was incubated on immobilized SAG in VB++ in the presence of inhibiting monoclonal 
antibodies anti-C1q-85 and anti-MBL/1. Anti-MBL/1 significantly reduced C4 deposition, 
whereas anti-C1q-85 only had a minor effect. Results represent mean and SEM (error bars) of 3 
MBL-sufficient donors.  
 
Unexpectedly, blocking of C1q caused only mild decrease in complement 
activation by SAG, (Fig. 3). Incubation with anti-MBL/1, however, blocked 
most C4 deposition on SAG, indicating that MBL plays the most important 
role in SAG induced complement activation. 
To further investigate whether MBL is responsible for C4 deposition on SAG 
we compared three MBL-sufficient sera with three MBL-deficient sera in 
parallel for complement activation by immobilized SAG. MBL levels of healthy 
volunteers were measured by ELISA and three sera with undetectable levels of 
MBL were selected for further experiments. Incubation with MBL-deficient sera 
resulted in drastically lower C4 deposition as compared with the MBL-sufficient 
sera (Fig. 4A). To ensure that complement activation was intact in the MBL-
deficient sera, a C4 deposition assay was performed on immobilized AHG. C4 
activation on AHG was completely normal in all tested sera (Fig. 4B), 
indicating that the observed differences between MBL-sufficient and -deficient 
sera could not be attributed to different functional C4 levels.  
 
Fucosylation of SAG is critical for complement activation 
Since SAG is a highly glycosylated protein with 25-40% of its molecular weight 
made up of carbohydrates it is very likely that, being a lectin, MBL binds to 
certain sugar residues on SAG. Three MBL sufficient sera were tested for C4 
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deposition on both untreated SAG and periodic acid treated SAG. As depicted 
in figure 5, both C4 deposition and MBL binding to SAG were strongly 
reduced after periodic acid treatment of SAG, indicating that the carbohydrates 
on SAG are responsible for complement activation, rather than the polypeptide 
part of the molecule. MBL is known to bind mannose, β-GlcNAc and α-L-
fucose containing carbohydrate moieties (Turner, 2003; Keshi et al., 2006). We 
investigated the presence of these carbohydrates on SAG-coated microplates 
with carbohydrate specific lectins (Fig. 6). We could detect fucose with UEA-1 
lectin, but we detected no GlcNAc with DSA lectin or mannose with GNA 
lectin. After periodic acid treatment fucose was not detected anymore. GlcNAc 
became detectable after periodic acid treatment, but mannose was still 
undetectable. Periodic acid did not affect SAG coating as shown with HYB 
213-06 antibody, which recognizes a peptide fraction of salivary agglutinin (Fig. 
6). These results show that complement activation corresponds with the 
availability of fucose on SAG. 
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Fig 4. C4 deposition on SAG in MBL-sufficient vs MBL-deficient sera. 
Serum obtained from both MBL-sufficient and MBL-deficient donors was incubated on (A) 
immobilized SAG or (B) immobilized AHG in VB++ or in VB/10 mM EDTA. Results represent 
mean and SEM (error bars) of 3 MBL-sufficient donors and 3 MBL-deficient donors.  
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Fig 5. Periodic treatment of SAG abolishes C4 deposition and MBL binding  
Immobilized SAG was treated with periodic acid (SAG/PA) or left untreated. Hereafter, C4 
deposition (A) was tested with serum diluted in Veronal buffer with Ca2+ and Mg2+ (VB++) or in 
Veronal buffer with 10 mM EDTA. In addition, MBL binding was detected on either untreated 
SAG or SAG/PA (B). Results represent mean and SEM (error bars) of 3 MBL-sufficient sera. 
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Fig 6. Detection of sugars on SAG, by lectin binding, after periodic acid treatment 
Immobilized SAG was either left untreated (A) or treated with periodic acid (B). HYB213-6 
antibody, raised against a peptide part of SAG, was used as a control for coating. Fucose was 
detected using UEA-1 lectin, GlcNAc was detected using DSA lectin and mannose detection 
was done using GNA lectin. Results represent mean and SD (error bars) of three samples. Of 
the potential MBL binding carbohydrates only fucose was available on untreated SAG. After 
treatment with periodate GlcNAc could by detected. 
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Discussion 
The present study confirms that SAG is able to activate the complement system 
as has been described before (Boackle et al., 1993). However, in this study we 
demonstrate that complement activation by SAG is primarily mediated by the 
lectin pathway and to a much lesser extent by the classical pathway. Although 
the latter had already been reported before (Boackle et al., 1993), the potent 
activation of the lectin pathway by SAG has not and may be relevant with 
respect to the physiological role of SAG at the mucosal lining. Moreover, the 
activation of the classical pathway has only been shown by the appearance of 
C1r-C1-inhibitor complexes on Western blot, which is not a quantitative assay. 
The observed classical pathway activation may thus be of minor importance 
compared to the lectin pathway. 
 
In our hands, blockage of C1q by use of an inhibiting anti-C1q monoclonal 
antibody showed a slight inhibiting effect on C4 deposition on SAG-coated 
plates which may explain the appearance of C1r-C1 complexes as described by 
Boackle et al. (1993) 
In contrast, blocking MBL binding with a monoclonal antibody, most C4 
deposition on SAG could be prevented indicating that the lectin pathway plays 
an important role in SAG mediated complement activation. This was 
confirmed by the incubation of MBL-deficient sera on immobilized SAG which 
resulted in very low C4 deposition. 
The remaining C4 activation that was observed in MBL-deficient sera, could 
not be inhibited by blocking the classical pathway of complement. In addition, 
co-incubation of anti-MBL and anti-C1q monoclonal antibodies never 
completely blocked C4 activation, indicating that another mechanism of C4 
activation exists on SAG. One possible explanation for the observed C4 
deposition in absence of MBL is ficolin mediated complement activation. 
Ficolins are recognition molecules that are very similar to MBL and also 
associated with MASPs, but recognizing different carbohydrate structures. 
Considering the heterogeneity of carbohydrates on SAG there might well be 
structures that are recognized by ficolins (Issa et al.).  
Next to mannose-containing carbohydrate structures MBL also recognizes 
GlcNAc- and fucose-containing glycans (Turner, 2003; Keshi et al., 2006). 
Complement activation by immobilized SAG, corresponded with the presence 
of fucose-residues, since after periodic acid treatment fucose was no longer 
detectable and both MBL binding and C4 deposition disappeared. The 
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carbohydrate chains on SAG are heavily fucosylated and contain blood group 
related structures like Lewisa/x and Lewisb/y antigens (Issa et al.). It will be 
interesting to investigate whether differences between individuals in 
glycosylation of SAG may result in differences in complement activation.  
MBL levels vary widely in the normal population and approximately 25% of 
the people in the Western world have strongly decreased functional MBL 
(Garred et al., 2003). A number of studies have shown that individuals with low 
levels of MBL have an increased risk for infections, particularly when immunity 
is already compromised: for example in infants, patients with cystic fibrosis, 
after chemotherapy and transplantation (Turner, 2003). It is tempting to 
speculate about a potential synergistic antimicrobial effect between SAG and 
MBL-mediated complement activation. Therefore, it would be interesting to 
investigate the prevalence of oral infections in relation to MBL levels. In 
addition, the effect of SAG on MBL-mediated opsonophagocytosis on yeasts 
and bacteria deserves further research.  
Although saliva is secreted in the oral cavity and serum is present inside the 
blood vessels interaction frequently occurs. In case of gingivitis, periodontal 
disease, but also after tooth brushing, serous exudates enter the oral cavity and 
mix with saliva (Henskens et al., 1996; Hoek et al., 2002; Giannobile et al., 
2009). Many salivary diagnostic tests, such as for HIV, are based on the 
presence of serum components in saliva (Malamud and Wahl). Serous exudates 
contain functional complement proteins that may interact with salivary proteins 
to potentiate their antimicrobial action. 
One question remains open whether complement activation by SAG is only 
beneficial to the host or can be detrimental as well. On the one hand, if SAG 
and MBL work synergistically leading to better phagocytosis of bacteria this 
could strengthen the host defence against oral infections. On the other hand, if 
complement activation by SAG leads to production of more pro-inflammatory 
complement split products such as C3a and C5a, this might eventually lead to 
increased influx of neutrophils thereby increasing inflammation in the oral 
cavity. The release of neutrophilic granule contents such as elastase or reactive 
oxygen species may induce more unwanted tissue damage giving more clinical 
problems. In periodontal disease, that is characterized by serum leakage in the 
mouth, reactive oxygen species have been described to play a role (Hu et al., 
2009).  
In conclusion, the present study demonstrates that the antimicrobial salivary 
protein SAG is capable of activating complement via the lectin pathway. The 
functional relevance of complement activation by SAG at the mucosal surfaces 
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remains to be investigated. The recently reported SAG-deficient mice (Madsen 
et al.; De Lisle et al., 2008) may be of help in this context. 
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Supplementary to Figure 1. Complement activation through AHG (A) or mannan (B). 
Microtiterplates were coated with AHG (A) or mannan (B) and incubated with serial dilutions 
of serum in VB++ buffer in the presence of anti-C1q-85 or anti-MBL/1. Anti-C1q-85 inhibited 
C4 deposition on AHG and anti-MBL/1 inhibited C4 deposition on mannan.  
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General Discussion 
The human oral cavity is inhabited by a wide variety of micro-organisms. One 
of the factors that play a dominant role in the maintenance of a healthy oral 
ecosystem is saliva. The crucial role of saliva becomes apparent when saliva 
secretion is impaired, e.g. in patients with the Sjögren’s syndrome, after 
radiation therapy, surgical removal of diseased salivary glands or as side effect of 
medication. Under these conditions a shift in the oral microflora may develop, 
resulting in the outgrowth of opportunistic pathogens, e.g. Candida albicans. 
Saliva contains numerous antimicrobial proteins and peptides that protect the 
oral tissue against microbial invasion and infection. These include proteins with 
bacteriostatic, bactericidal and fungicidal activity such as lysozyme, lactoferrin, 
cystatins and histatins (Nieuw Amerongen and Veerman, 2002; Tenovuo, 2002; 
Nieuw Amerongen et al., 2004; Ligtenberg et al., 2007). Other proteins, such as 
statherin, adsorb onto dental surfaces. By functioning as receptors for specific 
microbial adhesions they modulate the composition of the microflora on the 
tooth surface. Salivary proteins in solution, including immunoglobulins, 
particularly secretory-IgA, MUC7 and salivary agglutinin (SAG) bind and 
agglutinate oral bacteria promoting their removal from the oral cavity (Rossi et 
al., 2003; Ligtenberg et al., 2007; Kesimer et al., 2009). In this thesis especially 
the biological activity of two salivary components has been studied: salivary 
agglutinin (SAG) and statherin. 
SAG was originally discovered as a salivary component mediating 
agglutination of oral streptococci, in particular S. mutans (Ericson and 
Rundegren, 1983). Due to its ability to bind and agglutinate this cariogenic 
bacterium, SAG has been considered to play an important role in the protection 
against dental caries (Ericson and Rundegren, 1983; Carlen et al., 1998). SAG 
was characterized biochemically as a 300-400 kDa glycoprotein consisting for 
25 % of its molecular mass of carbohydrate residues. During years SAG was 
thought being specifically for saliva, particularly parotid saliva. However, in 
later studies it was proven that SAG, lung glycoprotein340 (gp340) and Deleted 
in Malignant Brain Tumours 1 (DMBT1) are all encoded by one and the same 
gene, namely the DMBT1 gene on chromosome 10. These proteins have 
identical protein sequences, but may be different in glycosylation. SAG is a 
member of the scavenger receptor cysteine-rich superfamily (SRCR) of proteins, 
a superfamily of surface-bound or secreted proteins typically possessing SRCR 
domains. Members of this group are usually involved in innate immune 
processes (Sarrias et al., 2004). SRCR domains consist of 110 amino acids and 
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their tertiary structure is stabilized by 3 or 4 disulfide bridges. SRCR domains 
are well conserved within all metazoa and usually are involved in ligand binding, 
as is the case with SAG. Bikker et al. (Bikker et al., 2002) demonstrated that the 
binding site for bacteria is located in the SRCR domains. The high homology of 
the SRCR domains in SAG justified the design of a consensus sequence. Based 
on this consensus sequence synthetic peptides were designed and tested for 
binding to bacteria. A 16-mer amino acid sequence 
(QGRVEVLYRGSWGTVC), derived from the SRCR domains of SAG 
(SRCR-P2), bound to a wide variety of micro-organisms. In Chapter 2 we 
showed that there is a good correlation between the binding of SAG and the 
SRCRP2 peptide to a wide variety of microbial species supporting the concept 
that the sequence encompassed by the SRCRP2 peptide represents the major 
bacteria-binding site of SAG. By truncation of the peptide combined with an 
alanine scan, Bikker et al. (Bikker et al., 2004) revealed an 11-mer peptide in 
which 6 amino acids were essential for binding of S. mutans 
(QGRVEVLYRGSWGTVC). We investigated in more detail the sequence that 
allows this peptide to bind to such a wide variety of bacterial species. We found 
that different residues are involved depending on the bacterium. In all cases are 
valine residues at position 4 and 6, tyrosine at position 8 and tryptophan at 
position 12 essential for binding. Amino acids that were often, but not always, 
involved in binding were arginine at position 3, glutamic acid at position 5, 
leucine at position 7 and serine at position 11. Of the SRCR-P2 residues that 
are always essential for binding, three out of four are highly conserved in the 
SRCR superfamily (Figure 1). A hidden Markov model logo of the SRCR 
domain shows that the valine residues at position 4 and 6, and tryptophan at 
position 12 were highly conserved within the SRCR superfamily, supporting 
the idea that these residues are functionally important. Also the bacteria-binding 
domain of two other SRCR proteins, Sp-α and CD 163, is homologous to 
SRCR-P2 fragment (Sarrias et al., 2005; Fabriek et al., 2009). 
The broad binding spectrum of SAG is typical for so called pattern 
recognition proteins. These are molecules that bind to conserved molecules on 
pathogenic micro-organisms, called pathogen associated molecular patterns 
(PAMPs), such as lipopolysaccharide, lipoteichoic acid and peptidoglycan. SAG 
was indeed shown to bind to LTA and phosphorylated groups on LPS (End et 
al., 2009). In Chapter 3 we show that SAG not only recognizes bacterial 
components, but also binds to C. albicans. Adhesion experiments in the 
presence of mannan showed no inhibition, suggesting that mannan is not the 
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PAMP recognized by SAG on the yeast surface. Future research should 
characterize the molecular binding between 
 
Fig. 1. Hidden Markov models logo of a fragment of the SRCR domain
visual tool for showing the degree of conservation within a protein family. The height of the 
amino acids represents their probability to be present in the protein family compared to the
background.  Different colors are given for amino acids of different charge and hydrophobicity. 
The amino acids 8-24 correspond with the SRCR
position 11 and 13, and tryptophan at position 20 are well conserved
peptide these amino acids were also essential for binding to bacteria. 
 
There is a number of differences between bacteria binding and 
binding of SAG. Binding of SAG to bacteria is abolished after chemical 
reduction of SAG. In contrast, the SAG
by chemical reduction. Another difference compared to bacteria binding is that 
adhesion of C. albicans to SAG coated surfaces is independent of Ca
binding of C. albicans to SAG shared some characteristics with that of binding 
to influenza virus, that binds to sialic acid residues on SAG. This binding is also 
independent of Ca2+-ions and not affected by chemical reduction 
al., 2003).  
 In Chapters 4 and 5 the effect of saliva on hyphae formation of 
was studied. C. albicans is a multimorphic fungus growing in yeast form or 
hyphae form. Hyphae are more adhesive and more virulent than yeasts, the 
predominant form in the oral cavity. Ogasawara 
showed that bovine salivary mucins inhibited hyphae formation of 
Therefore, we investigated in which way human saliva influences hyphae 
growth of C. albicans. We found that saliva induces transition to yeast growth 
under conditions favouring hyphae formation. Since mucin
also induced yeast growth, we speculated that SAG, which is the most mucin
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like molecule in parotid saliva, might be responsible for transition to yeast 
growth. However, purified SAG did not show any effect on this process, 
prompting us to search for another parotid component promoting yeast-
induction. By fractionation of parotid saliva it was shown that the salivary 
statherin, 43-mer peptide, was responsible for this activity. Testing of truncated 
variants of statherin for yeast growth induction revealed that deletion of the 
negatively charged N-terminal amino acids in StN6-43 enhanced the hyphae 
inhibiting activity. Possibly, there is repulsion between the negatively charged 
cell surface and the negatively charged N-terminus of statherin. This was also 
suggested by the finding that StN6-43 binds better to C. albicans than the full 
length statherin. The hyphae inhibiting activity was further increased by 
deletion of another 4 amino acids at the N-terminus (StN10-43), but in this 
case no further negative charges are deleted. Binding of this peptide to C. 
albicans was comparable with StN6-43.  
 Inhibition of hyphae formation is a new protective mechanism by which 
saliva may prevent C. albicans infection. Hyphae formation may be triggered by 
all kinds of different stimuli, for instance by addition of serum or N-
acetylglucosamine to growth medium, or by growth at 37 ºC. These 
circumstances trigger the expression of genes that induce hyphae formation. It 
will be interesting to investigate the effect of statherin on the expression of 
hyphae inducing genes.  
 
SAG and complement  
SAG has been implicated in the protection of the oral tissue against 
bacterial colonization (Madsen et al.; Carlen et al., 1998; Ligtenberg et al., 2007; 
Leito et al., 2008). This has generally been attributed to its binding and 
agglutination of a wide variety of micro-organisms. However, SAG is only a 
minor component in saliva, making up less than 1% of the salivary protein 
content. Other bacteria-binding proteins, such as S-IgA, proline-rich 
glycoprotein and MUC7 are much more predominant in saliva. Therefore, it is 
tempting to speculate that inhibition of bacterial colonization is not the only 
physiological function of SAG. An earlier study by Boackle et al. (Boackle et al., 
1993) suggested that SAG is also able to activate the complement system, an 
amplifying cascade of proteolytic cleavages of specific proteins in the blood and 
tissues, which cooperates with the adaptive immune system in the clearance of 
pathogens from the body. Under healthy conditions, little if any interaction 
takes place between saliva and the complement system. However, in individuals 
with oral infections, such as periodontal disease, serum exudates will mix with 
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saliva at the gingival margin, resulting in mutual interaction between salivary 
and serum defensive systems such as the blood coagulation system (Berckmans 
et al.) and the complement system (Boackle et al., 1993). In Chapter 6 we 
investigated in more detail the molecular basis underlying the SAG-mediated 
activation of the complement system.  
Three biochemical pathways activate the complement system: the 
classical pathway, the lectin pathway and the alternative pathway (Figure 2).  
1. The classical pathway is triggered when antibody-antigen 
complexes bind to C1q, a part of the C1 complex.  
2. The lectin pathway is activated by binding of mannose-
binding lectin (MBL) or ficolins to carbohydrate residues on 
the surface of micro-organisms. The classical and lectin 
pathway both lead to C4 activation which is not the case in 
the alternative pathway.  
3. The alternative pathway is initiated by spontaneous hydrolysis 
of complement factor C3 to C3a and C3b. In the absence of 
a pathogen, these fragments will rejoin, resulting in 
deactivation. When C3b encounters a pathogen, it will bind 
covalently to its surface. This initiates a cascade of processes 
leading to further activation of C3.  
All three pathways ultimately lead to activation of C3-convertase. This protease 
causes a further cascade of proteolytic activations, ultimately generating a 
number of active products that stimulate a variety of immune-related processes, 
such as opsonization, chemotaxis, vascular permeabilization and formation of 
the membrane-attack complex, the cytolytic endproduct of the complement 
cascade. 
Boackle et al. (1993) showed that SAG was able to activate the 
complement system through the classical pathway. However, by analysis of the 
downstream processes we demonstrated in Chapter 6 that SAG activates the 
complement system mainly via the MBL pathway. Complement activation by 
SAG resulted in C4 deposition and was blocked by anti-MBL antibodies, 
whereas anti-C1q had no effect. Furthermore, with MBL-deficient sera no 
SAG-mediated complement activation occurred.  
Complement activation by SAG was putatively mediated by fucose-
containing oligosaccharides on SAG, since removal of this carbohydrate 
abolished the SAG-mediated complement activation. Since fucose residues are 
present on other salivary glycoproteins, e.g. the salivary mucins, as well, it will 
be interesting to investigate to what extent these are also able to activate the 
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complement system. The presence and availability of fucose epitopes in on 
salivary glycoproteins shows large interindividual variation and depends on, 
among other things, the blood group and secretor status. Future research should 
find out whether differences in glycosylation of SAG determine activation of 
complement.  
The effect of SAG on complement activation is only a first step in 
investigating the role of complement activation in the oral cavity. Future 
research should find out which other salivary proteins are involved in 
complement activation and what the effect of complement activation is on oral 
bacteria.  
 
Conclusively, we can state that two novel issues of the salivary defence are 
addressed in this thesis.  
- First, the role of SAG in the innate immunity seems not to be restricted to 
direct clearance of bacteria, but probably also involves activation of the 
complement system in serum exudate.  
- Second, next to these defence mechanisms, a novel antimicrobial defence 
mechanism in saliva was discovered, namely the statherin-mediated inhibition 
of hyphae formation by the yeast C. albicans.  
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Fig. 2. The complement system. There are three pathways of complement activation, shown 
at the top of the figure, the classical(1), lectin (2) and alternative (3) pathway.  
(1) Binding of the C1 complex initiates the classical pathway.  
(2) Binding of the MBL/MASP-2 comlex initiates the lectin pathway. Both the classical 
and lectin pathway lead to cleavage of  C4 and C2 resulting in formation of 
C3convertase.   
(3) The alternative pathway is initiated by spontaneous hydrolysis of C3, leading to 
formation of C3a and C3b. If there is no pathogen C3a and C3b will rejoin . In the 
presence of pathogenic surfaces C3b will bind leading to the formation of C3 
convertase of the alternative pathway.   
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All three pathways lead to activation of C3 in C3a and C3b. C3b contributes to 
the formation of C5 convertase, which initiates formation of the membrane 
attack complex. 
 
Chapter 7   
128 
 
References 
Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-
derived vesicles exposing coagulant tissue factor in saliva. Blood 
117:3172-3180. 
Bikker FJ, Ligtenberg AJM, End C, Renner M, Blaich S, Lyer S, Wittig R, van't 
Hof W, Veerman ECI, Nazmi K, de Blieck-Hogervorst JMA, Kioschis 
P, Nieuw Amerongen AV, Poustka A, Mollenhauer J. 2004. Bacteria 
binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW 
motif in its scavenger receptor cysteine-rich domains. Journal of 
Biological Chemistry 279:47699-47703. 
Bikker FJ, Ligtenberg AJM, Nazmi K, Veerman ECI, van't Hof W, Bolscher 
JGM, Poustka A, Nieuw Amerongen AV, Mollenhauer J. 2002. 
Identification of the bacteria-binding peptide domain on salivary 
agglutinin (gp-340/DMBT1), a member of the scavenger receptor 
cysteine-rich superfamily. Journal of Biological Chemistry 277:32109-
32115. 
Boackle RJ, Connor MH, Vesely J. 1993. High molecular weight non-
immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads 
and have the potential to activate the first complement component. Mol 
Immunol 30:309-319. 
Carlen A, Bratt P, Stenudd C, Olsson J, Stromberg N. 1998. Agglutinin and 
acidic proline-rich protein receptor patterns may modulate bacterial 
adherence and colonization on tooth surfaces. J Dent Res 77:81-90. 
End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S, Hudler M, 
Helmke B, Gassler N, Autschbach F, Ligtenberg AJM, Benner A, 
Holmskov U, Schirmacher P, Nieuw Amerongen AV, Rosenstiel P, Sina 
C, Franke A, Hafner M, Kioschis P, Schreiber S, Poustka A, 
Mollenhauer J. 2009. DMBT1 functions as pattern-recognition 
molecule for poly-sulfated and poly-phosphorylated ligands. Eur J 
Immunol 39:833-842. 
Ericson T, Rundegren J. 1983. Characterization of a salivary agglutinin reacting 
with a serotype c strain of Streptococcus mutans. Eur J Biochem 
133:255-261. 
 General Discussion 
129 
 
Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, 
Vloet RP, Dijkstra CD, van den Berg TK. 2009. The macrophage 
scavenger receptor CD163 functions as an innate immune sensor for 
bacteria. Blood 113:887-892. 
Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. 
2003. Lung and salivary scavenger receptor glycoprotein-340 contribute 
to the host defense against influenza A viruses. Am J Physiol Lung Cell 
Mol Physiol 285:L1066-1076. 
Kesimer M, Kilic N, Mehrotra R, Thornton DJ, Sheehan JK. 2009. 
Identification of salivary mucin MUC7 binding proteins from 
Streptococcus gordonii. BMC Microbiol 9:163. 
Leito JTD, Ligtenberg AJM, Nazmi K, de Blieck-Hogervorst JM, Veerman ECI, 
Nieuw Amerongen AV. 2008. A common binding motif for various 
bacteria of the bacteria-binding peptide SRCRP2 of DMBT1/gp-
340/salivary agglutinin. Biol Chem 389:1193-1200. 
Ligtenberg AJM, Veerman ECI, Nieuw Amerongen AV, Mollenhauer J. 2007. 
Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with 
variable composition and with different functions in infection, 
inflammation and cancer. Biol Chem 388:1275-1289. 
Madsen J, Mollenhauer J, Holmskov U. Review: Gp-340/DMBT1 in mucosal 
innate immunity. Innate Immun 16:160-167. 
Nieuw Amerongen AV, Veerman ECI. 2002. Saliva--the defender of the oral 
cavity. Oral Dis 8:12-22. 
Nieuw Amerongen AV, Bolscher JGM, Veerman ECI. 2004. Salivary proteins: 
protective and diagnostic value in cariology? Caries Res 38:247-253. 
Ogasawara A, Komaki N, Akai H, Hori K, Watanabe H, Watanabe T, Mikami 
T, Matsumoto T. 2007. Hyphal formation of Candida albicans is 
inhibited by salivary mucin. Biological & Pharmaceutical Bulletin 
30:284-286. 
Rossi GA, Peri C, Raynal ME, Defilippi AC, Risso FM, Schenone G, Pallestrini 
E, Melioli G. 2003. Naturally occurring immune response against 
bacteria commonly involved in upper respiratory tract infections: 
analysis of the antigen-specific salivary IgA levels. Immunol Lett 86:85-
91. 
Chapter 7   
130 
 
Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, Lozano F. 2004. 
The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and 
highly conserved protein module of the innate immune system. Crit 
Rev Immunol 24:1-37. 
Sarrias MR, Rosello S, Sanchez-Barbero F, Sierra JM, Vila J, Yelamos J, Vives J, 
Casals C, Lozano F. 2005. A role for human Sp alpha as a pattern 
recognition receptor. J Biol Chem 280:35391-35398. 
Tenovuo J. 2002. Antimicrobial agents in saliva--protection for the whole body. 
J Dent Res 81:807-809. 
 
 
 
 
 
  
 
Nederlandse Samenvatting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15Wat is, was er reeds lang, en wat zijn zal, is reeds lang geweest; en God zoekt weer op, wat voorbijgegaan is. 
prediker 3:15
   
 
132 
 
Inleiding 
In de mond zijn honderden soorten bacteriën aanwezig in enorme aantallen; 1 
ml speeksel bevat ongeveer 100 miljoen bacteriën. Ondanks deze enorme 
aantallen bacteriën hebben wij weinig last van infecties en met goede 
mondhygiëne kunnen wij ons leven lang doen met onze tanden. Anders wordt 
de situatie bij mensen die te weinig speeksel produceren, bijvoorbeeld na 
bestraling, bij medicijngebruik of bij het syndroom van Sjögren. Deze mensen 
hebben, naast problemen met spreken, kauwen en slikken, ook moeite met het 
gezond houden van de mond. De tanden zijn gevoeliger voor slijtage en cariës, 
en tong, verhemelte en wangen zijn gevoeliger voor infectie.  
Om de mond gezond te houden bevat speeksel een hele set aan eiwitten die 
betrokken zijn bij de afweer. Deze eiwitten doden bacteriën of remmen de 
bacteriegroei, zoals lysozym, lactoferrine, histatinen en cystatinen. Daarnaast 
zijn er eiwitten die aan bacteriën binden en daarmee bacteriële hechting aan het 
tandoppervlak verhinderen, zoals agglutinine, S-IgA en MUC7. In dit 
proefschrift is de antimicrobiële werking van twee speekseleiwitten bestudeerd, 
speeksel agglutinine (SAG) en statherine. 
 
Binding van SAG aan micro-organismen 
Cariës is wereldwijd één van de meest voorkomende infectieziekten. Cariës 
wordt veroorzaakt door bacteriële omzetting van suikers in zuren. Door deze 
omzetting daalt de pH in de mond wat de groei van de meeste bacteriën remt. 
Frequente consumptie van suiker genereert een groot aantal langdurige 
zuurmomenten in de tandplak, waardoor bacteriën die ook nog bij lage pH 
doorgaan met zuurvorming uit suiker een selectief voordeel hebben en 
toenemen in aantal. Dit zijn de zogenaamde cariogene bacteriën die ervoor 
zorgen dat de zuurmomenten intenser worden en er cariës kan ontstaan. Eén 
van deze cariogene bacteriën is Streptococcus mutans. In het verleden is 
onderzocht welke speekseleiwitten kunnen binden aan S. mutans en daarmee 
mogelijk de kolonisatie beïnvloeden. SAG werd geïdentificeerd als één van de 
belangrijkste S. mutans bindende eiwitten in speeksel. SAG is een eiwit van 
ongeveer 340.000 dalton en bestaat voor een kwart van de massa uit 
koolhydraatketens. SAG komt niet alleen in speeksel voor, maar ook in tranen 
en longvloeistof, waar het bekend staat als gp340. SAG en gp340 worden beide 
afgelezen van het DMBT1 gen op chromosoom 10. DMBT1 staat voor Deleted 
in Malignant Brain Tumours 1, omdat dit gen inactief is in bepaalde vormen 
van hersentumor. SAG behoort tot de Scavenger Receptor Cysteine Rich 
(SRCR) superfamilie van eiwitten. SRCR eiwitten komen in alle meercellige 
  
dieren voor. Het zijn eiwitten met veel verschillende functies, die 
gemeenschappelijk hebben dat ze allemaal SRCR eiwitdomeinen bezitten. 
Eiwitdomeinen zijn geconserveerde stukjes eiwit die in vers
organismen voorkomen. Op dit SRCR domein van 109 aminozuren ligt het 
bacterie-bindende gedeelte van SAG, een stukje van 16 aminozuren (Figuur 1). 
Wij vonden dat er een sterk verband is tussen de binding van een bacterie aan 
dit kleine gedeelte van dit eiwit (peptide) van 16 aminozuren en de binding aan 
het hele eiwit, wat erop wijst dat dit onderdeel
voor bacteriën (Hoofdstuk 2). Door varianten van dit 
waar telkens één aminozuur is vervangen door het aminozuur alanine, kon 
worden onderzocht hoe belangrijk elk aminozuur is voor de binding aan een 
bacterie. Door deze verschillende 16-aminozuur
groot aantal bacteriën konden wij aantonen dat voor d
verschillende micro-organismen verschillende aminozuren essentieel zijn.
aminozuren waren echter altijd belangrijk voor de binding aan bacteriën. Drie 
daarvan zijn goed geconserveerd binnen andere SRCR eiwitten
tweemaal valine en eenmaal tryptofaan,
andere SRCR eiwitten een belangrijke functie heeft. 
 
Figuur 1. Speeksel agglutinine is een eiwit dat bestaat uit SRCR domeinen, CUB domeinen en 
een zona pellucida (ZP) domein. Omdat het bacte
ligt zijn van het SRCR domein 7 fragmenten synthetisch gemaakt en getest op bacteriebinding. 
Alleen het tweede fragment  (SRCRP2) is in staat bacteriën te binden. 
     
         
Naast het binden van bacteriën is SAG ook in staat te binden aan de schimmel 
Candida albicans (Hoofdstuk 3). Candida albicans
bevolking voor in de mond, maar doet bij de meeste mensen weinig kwaad. 
Wanneer er echter problemen zijn met de afweer in de mond, zoals bij een 
tekort aan speeksel of bij gebruik van afweeronderdrukkende medicijnen, kan 
deze schimmel uitgroeien en infecties veroorzaken, in de volksmond bekend 
onder de naam spruw. Wij vonden dat SAG bindt aan 
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ten opzichte van SAG binding aan bacteriën enkele essentiële verschillen zijn. In 
tegenstelling tot binding aan bacteriën was hechting aan C. albicans 
onafhankelijk van calcium-ionen en had chemische reductie van SAG geen 
invloed op de binding.  
 
Remming van hyfenvorming van Candida albicans 
C. albicans komt in twee verschillende vormen voor; als ronde gistcellen en als 
draadvormige hyfen. De gistvorm hecht minder sterk aan diverse oppervlakken 
en kan zich makkelijk verspreiden. De hyfenvorm van C. albicans daarentegen 
hecht sterk aan diverse oppervlakken en kan in weefsel binnendringen en is 
daarom over het algemeen veel infectieuzer dan de gistvorm. In een gezonde 
mond komt C. albicans vrijwel alleen in de gistvorm voor. Daarom 
onderzochten wij of er in speekseleiwitten zijn die ervoor zorgen dat C. albicans 
als gistvorm groeit. Wij vonden dat het eiwit statherine ervoor zorgt dat C. 
albicans als gistvorm groeit onder omstandigheden die normaal hyfengroei 
veroorzaken. Statherine is een klein eiwit van 43 aminozuren. De eerste vijf 
aminozuren van het eiwit hebben een sterk negatieve lading. Hierdoor kan het 
eiwit goed calcium binden en speelt het een rol bij het herstellen 
(remineraliseren) van het tandglazuur na beschadiging door bijvoorbeeld zuur 
snoepgoed. Het eiwit is ook een belangrijke bindingsplaats voor bacteriën uit 
tandplaque. Door het eiwit systematisch in te korten vonden wij dat weglaten 
van de eerste 5 aminozuren de gistgroei versterkte. Door weglaten van dit 
fragment wordt het eiwit minder negatief geladen waardoor het sterker bindt 
aan het negatief geladen oppervlak van C. albicans. Verder inkorten toonde aan 
dat het statherine fragment waarin de eerste 10 aminozuren ontbreken de 
sterkste gistgroei gaf. De meeste fragmenten die een goede gistgroei 
veroorzaakten, waren ook in staat om hyfen los te weken van de kweekplaat wat 
zou kunnen wijzen op een gemeenschappelijke oorzaak voor beide 
verschijnselen. Er waren echter ook peptiden die hyfengroei remden, maar de 
hyfen niet losweekten van de kweekbodem, en peptiden die alleen de hyfen 
losweekten van de kweekbodem zonder gistgroei te veroorzaken. Dit wijst erop 
dat het stimuleren van gistgroei en het losweken van de kweekbodem twee 
verschillende oorzaken heeft.  
 
Complement activering door SAG 
Wanneer wij de concentratie van SAG in speeksel vergelijken met andere 
bacteriebindende eiwitten, zoals MUC7 en S-IgA, is die concentratie veel lager. 
Dit deed ons vermoeden dat remming van aanhechting niet de belangrijkste 
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functie is van SAG, maar dat SAG mogelijk een signaalfunctie heeft en 
bijvoorbeeld bepaalde afweerreacties activeert. Voorgaand onderzoek heeft 
aangetoond dat SAG in staat is het complementsysteem te activeren. Het 
complementsysteem is een systeem van serum eiwitten dat een belangrijke rol 
speelt bij de afweer tegen micro-organismen. Door binding aan micro-
organismen worden enzymen geactiveerd, die weer een volgend enzym activeren. 
Uiteindelijk resulteert dit in fagocytose door immuun-cellen, aantrekken van 
immuun-cellen of directe doding van de micro-organismen. Er zijn drie 
manieren waarop het complement systeem geactiveerd kan worden.  
(1) De klassieke route: Antigen-antilichaam complexen hechten aan C1q, 
het eerste eiwit wat bij de klassieke route een rol speelt. 
(2)  De lectine route: Mannose bindend lectine (MBL) of ficoline hecht aan 
suikerstructuren op het celoppervlak van een micro-organisme, wat een 
enzym activeert. 
(3) De alternatieve route: Een derde mogelijkheid is dat het complement 
systeem zichzelf activeert door splitsing van het C3 eiwit in C3a en C3b. 
Wanneer er geen micro-organisme in de buurt is associeert C3 weer, 
maar wanneer er wel een micro-organisme aanwezig is bindt C3b zich 
covalent aan het micro-organisme wat ervoor zorgt dat de 
complementreactie wordt voortgezet op het oppervlak van het micro-
organisme. 
 
  
 
             
Figuur 2. Schematisch overzicht van de activering van het 
route en lectine route leiden beide tot activering van C4.  Activering van C4 leidt tot vorming 
van C3 convertase. De alternatieve route wordt geactiveerd door spontane hydrolyse van C3 die 
na binding met factor-B  een C3 convertase vormt.  
 
Voorgaand onderzoek toonde aan dat SAG het complement systeem activeert 
door binding aan C1q en dus waarschijnlijk de klassieke 
complement systeem activeert. Door het meten van C4 depositie konden wij 
bevestigen dat SAG het complement systeem activeert. C4 is een eiwit wat een 
rol speelt bij de activering van het complementsysteem volgens de klassieke en 
lectine route, maar niet volgens de alternatieve route. Antilichamen tegen C1q, 
die de klassieke activeringsroute remmen, hadden weinig effect op de 
complement activering door SAG. Antilichamen tegen MBL waren 
in staat activering door SAG te remmen. Circa 20 % van de bevolking maakt 
geen of zeer geringe hoeveelheden MBL. Het complement systeem in serum van 
deze mensen werd nauwelijks geactiveerd door SAG. Deze gegevens wijzen erop 
dat SAG het complementsysteem via de MBL route activeert en niet via de 
klassieke route.  
Om te achterhalen hoe SAG de MBL route activeert hebben we onderzocht of 
MBL suikerstructuren op SAG herkent. Hiervoor werd SAG met perjodaat 
bewerkt, wat suikerstructuren oxideert, en getest o
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een perjodaat bewerking was SAG niet meer in staat het complementsysteem te 
activeren, wat erop wijst dat MBL suikerstructuren herkent op SAG. Het 
verdwijnen van de complement activering liep parallel met het verdwijnen van 
fucoseresiduen, wat erop wijst dat MBL waarschijnlijk aan fucoseresiduen op 
SAG bindt.  
 
Conclusies  
In dit onderzoek worden twee nieuwe beschermingsmechanismen in speeksel 
beschreven. Het eerste mechanisme is dat statherine de hyfengroei van C. 
albicans remt. Het tweede mechanisme is dat SAG in staat is het 
complementsysteem te activeren. Dit laatste mechanisme is een aanwijzing dat 
speeksel en bloed kunnen samenwerken bij de afweer tegen micro-organismen 
die via de mondholte ons lichaam binnendringen.  
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